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ABSTRACT

Cancer is a disease that has eluded medicinal approaches for many years and as a result
new and improved therapeutic approaches are in constant demand. Although chemotherapy and
radiation treatments have assisted in suppressing the growth of tumors, their poor selectivity and
efficacy are major limitations for effective therapy en route towards the development of a cure for
the cancer epidemic. With the mission of conquering cancer at heart, researchers have pursued a
new form of cancer therapy, aptly named, a cancer targeting approach. This method revolves
around the selection of a suitable biomarker, typically a cell surface receptor overexpressed or
selectively localized on the surface of cancer cells but not on normal tissues. This biomarker forms
the basis of a cancer targeting approach, in which high affinity and specific binding ligands (e.g.
peptides) have been selected by phage display bio-panning methods or combinatorial chemistry to
target cancer cells in-vivo.
Building on this approach, the identification of a cyclic peptide, Pep42, H2NCTVALPGGYVRVC-CONH2, has been selected as a specific and high-affinity binding ligand of
the cell surface receptor, Glucose Regulated Protein 78 (GRP78). GRP78 is a member of the heat
shock family of chaperone proteins, assisting in protein folding events under physiological stress
induced conditions that are mitigated by the unfolded protein response (UPR) mechanism. In
cancer, GRP78 is overexpressed and cell surface localized where it functions as a hub for cell
signaling pathways that lead to cancer cell initiation, proliferation and resistance towards
chemotherapy. Thus, GRP78 has been classified as a valid biomarker for the development of
targeted anti-cancer approaches.
Towards this goal, an Fmoc-based solid phase peptide synthesis (Fmoc-SPPS) method has
been optimized on a polyethylene glycol (PEG) resin for the production of poly(arginine) derived
iv

Pep42 sequences in good yields (14-46%) and purities (>95%) following RP-LCMS. The effect
of the length (0-12) and stereochemistry (L/D) of the poly(arginine) sequences on Pep42 structure
and stability were next evaluated by CD spectroscopy. Interestingly, peptides displayed varying
folded conformations, transitioning between helical and turn structures, that were found to be
contingent on the poly(arginine) sequence, solvent and disulfide bond formed within the Pep42
motif. Moreover, the peptide folds were found to be resilient towards thermal denaturation due to
the covalent disulfide bond.
Structure-activity relationships were next assessed in HepG2 hepatoblastoma cells, in
which the cancer-targeting peptides were found to bind to the GRP78 receptor and internalize
within the HepG2 cells. This discovery has led to their applications in cancer-targeted gene
therapy, from which a GRP78-silencing short-interfering RNA (siRNA) was effectively
transfected within the HepG2 cells for potent oncogene knockdown effects (50-60%, 40 pmol
siRNA) while triggering modest cell death effects (5-10%). This thesis will highlight my efforts
and contribution in collaboration with Drs. Blake and Bitsaktsis research groups towards the
development of an effective cancer-targeted gene therapy approach.
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2.1, sequence 2.8, 50 µM).
Figure A38

CD spectra for Pep42-r12 (Table 2.1, sequence 2.9, 50 µM) in water,
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TFE and PBS at 25 °C

Figure A39

Temperature dependent (25 – 85 oC) CD spectra for Pep42-r12
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(Table 2.1, sequence 2.9, 50 µM).
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Figure A40

Flow cytometry data on HepG2 cells.
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Figure A41

Laser scanning confocal microscopy of HepG2 cells.

150

Figure A42

Native PAGE gel shift assay of siRNA:CTP (1:1-50 mol:mol, 1.0
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µmol).

Figure A43

CD spectra of siRNA:Pep42 complexes (13 μM, 1-50:1 mol/mol) in
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PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM
KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A44

CD spectra of siRNA:Pep42-R3 complexes (13 μM, 1-50:1 mol/mol)
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in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM
KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A45

CD spectra of siRNA:Pep42-R12 complexes (13 μM, 1-50:1 mol/mol)
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in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM
KH2PO4 adjusted to pH 7.4) at 25 oC.
Figure A46

CD spectra of siRNA:R9 complexes (13 μM, 1-50:1 mol/mol) in PBS
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(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4
adjusted to pH 7.4) at 25 oC.

Figure A47

CD spectra of branch siRNA(Y):Pep42-R3 complexes (13 μM, 1-50:1
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mol/mol) in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0
mM KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A48

CD spectra of branch siRNA(Y):Pep42-R9 complexes (13 μM, 1-50:1
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mol/mol) in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0
mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A49

CD spectra of branch siRNA (Y):Pep42-R12 complexes (13 μM, 1-
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50:1 mol/mol) in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A50

CD spectra of hyperbranch siRNA (1-2):Pep42-R3 complexes (13 μM,
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1-50:1 mol/mol) in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A51

CD spectra of hyperbranch siRNA (1-2):Pep42-R9 complexes (13 μM,
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1-50:1 mol/mol) in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A52

CD spectra of hyperbranch siRNA (1-2):Pep42-R12 complexes (13
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μM, 1-50:1 mol/mol) in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.

Figure A53

TEM image of Pep42-R9 showing different populations.
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Figure A54

TEM images of branch siRNA generating well distributed uniform
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particles, average size 20-25 nm.
Figure A55

TEM images of branch siRNA:CTP-R9 complex.
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Figure A56

TEM image of hyperbranch siRNA.
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Figure A57

TEM image of hyperbranch siRNA:Pep42-R9.
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Figure A58

Thermal denaturation studies of the siRNA (duplex):Pep42 complex.
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Figure A59

Thermal denaturation studies of the branch siRNA(Y):Pep42-R3
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complex.
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Figure A60

Thermal denaturation studies of the siRNA (duplex):Pep42-R3
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complex.

Figure A61

Thermal denaturation studies of the hyperbranch siRNA (1-2):Pep42-
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R3 complex.
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CHAPTER 1: CANCER-TARGETING
APPLICATIONS
IN
ANTI-CANCER
DEVELOPMENT

PEPTIDES AND THEIR
DRUG
DESIGN
AND

1.1 CANCER-TARGETING APPROACHES
Anti-cancer drugs that are designed and fabricated to destroy cancer cells often do so nonselectively, rapidly dispersing in all tissue types rendering patients with severe side-effects that
compromises the road to recovery.1 Moreover, the bioavailability and tissue penetration properties
of anti-cancer drugs based on biomacromolecules such as oligonucleotides,2 peptides3 and
carbohydrates4 results in limited passive diffusion through the phospholipid bilayer for cancer cell
death activity. These major impediments have stimulated the search and application of alternative
anti-cancer drug delivery methods that aim to a) target cancer cells exclusively, while b)
facilitating the internalization of cytotoxic drugs that can trigger cancer cell death (Figure 1.1).

Figure 1.1. Cancer-targeting approaches. Figure adapted from Wu, H-C. et al J. Cancer Mol. 2006, 2, 5766.28

Antisense oligonucleotides target oncogene expression compromising cancer cell activity.
Immunotherapy uses antibodies to bind to cell surface tumor presenting antigens recruiting the
immune response. Selective small molecule inhibitors can be designed to bind specifically and
1

with high affinity to tumor cell overexpressing metalloproteinases and kinases. Specific
modulators of angiogenesis and apoptosis can also target cancer cell death.
Towards this effect, antibodies have served as Mother Nature’s targeting biomolecules.
They contain the ability to detect and bind to specific antigens on invading pathogens, allergens
and cancers while recruiting the immune response for their eradication.5,6 However, many types
of resilient cancers have evolved to evade recognition of our natural immune system, and continue
to proliferate without restriction forming the most resistant types of malignant tumors. In an
attempt to rescue our immune response from cancer, monoclonal antibodies (mAb) targeting
specific cancer cell surface markers that are vital to tumorigenesis and metastasis have been
designed and validated in a clinical method referred to as cancer immunotherapy (Figure 1.2).6
Using recombinant gene expression, mutagenesis and molecular evolution procedures, mAb retain
the immunostimulatory effects of their naturally occurring counterparts, while recognizing cell
surface antigens that were previously camouflaged on cancer cells.

Figure 1.2. Cancer immunotherapy approach.6 a) Antibody Dependent Cell Cytotoxicity (ADCC)
mechanism activates NK cell secretion of perforin and granzyme tumor cell lysis enzymes, b) Phagocytosis
leads to lysosomal degradation of tumor cells from the mAb-macrophage binding interaction and c) Crosspresentation leads to mAb-antigen (MHC class I and II) recognition on tumor derived dendritic cells for T
cell activation and cytotoxicity. Figure adapted from Weiner, L.M. et al Nature Rev. Immunol. 2010, 10,
317-327.
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Moreover, these methods have facilitated the bio-conjugation of anti-cancer drugs,7
radionuclides,8 toxins9 and imaging agents10 that have ushered a new wave of Food and Drug
Administration (FDA) approved drugs for cancer diagnosis and treatment in the clinic.6,11 In spite
of their growing success, mAb and their bio-conjugates still retain severe limitations that prevent
their widespread use as therapeutics.11 mAb-based treatments are still affected by lengthy and
expensive production costs associated with large-scale cell culture, bio-conjugation and
purification methods. In addition to poor stability and pharmacokinetic properties which limits
tumor tissue penetration for effective immunotherapy. Immunostimulatory-associated toxicities
have also been found in patients that are immuno-compromised following exhaustive chemo- and
radio-therapeutic treatments. Thus, the need to develop simpler, benign and effective modes of
cancer therapy remains an elusive goal in the fight against cancer.
Inspired by their mAb counterparts, cancer-targeting peptides (CTPs) have emerged as
fruitful types tumor-targeting ligands. They favor high affinity and selective binding to cancer cell
surface receptors, while enabling membrane translocation for activity (Figure 1.3).12 Moreover,
CTPs and related analogs have led to the development of potent anti-cancer bioconjugates,
endowed with favorable pharmacokinetic properties and armed with imaging agents,
radionuclides, cytotoxic drugs or toxins that have improved detection and therapy.13-17 For
example, an RGD peptide, known to associate on cell surface integrin receptors overexpressed and
membrane localized on solid tumor tissues have been conjugated with fluorescent probes to effect
in-vivo tumor imaging in mice bearing tumor models.13 Moreover, the RGD peptides have also
been labeled with In-DOTA containing radionuclides for halting and shrinking tumor growth in
human tumor xenograft models.14,16 The conjugation of camptothecin as an apoptosis inducing
agent with a leutinizing-hormone releasing hormone (LHRH, QHWSYkcLRPNHEt) resulted in
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an accumulation in the tumor of mice bearing xenografts of A2780 human ovarian carcinoma with
minimal dispersion to other tissues. This resulted in amplified induction of apoptosis in the tumor
site as compared to treatment with camptothecin alone.17 As a result, CTPs have provided a safe
and effective alternative in cancer treatment methods. They effectively circumvent the limitations
and cytotoxicities associated with the recombinant mAbs and the non-selective forms of cancer
therapy.

Figure 1.3. Design of cancer-targeting peptides.

1.2 PREPARATION OF CANCER-TARGETING PEPTIDES
Combinatorial chemistry involves the synthesis or biosynthesis of chemical libraries (a
family of compounds having a base chemical structure) of molecules for the purpose of biological
screening, leading to the discovery of a lead for further optimization and application.18 The field
of combinatorial chemistry has become a powerful tool in drug discovery especially applied to
cancer-targeting peptides. There are six general methods for preparing and screening
combinatorial libraries of peptides leading to the discovery of lead ligands for high affinity and
selective oncoprotein binding.19 These include:
I.

The biological peptide library method (phage-display peptide library)

II.

The one-bead-one-compound (OBOC) combinatorial library method
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III.

The spatially addressable parallel library method

IV.

Combinatorial library methods requiring deconvolution

V.
VI.

The affinity selection method
Self-assembled peptide nucleic acid (PNA) encoded chemical microarrays

However, of these six methods, only the phage-display peptide library and the OBOC method have
been applied to the discovery of cancer cell receptor-targeting peptides and will be highlighted in
this chapter.
1.2.1 COMBINATORIAL PEPTIDE CHEMISTRY
Combinatorial chemistry was originally used to make peptide libraries from the multipin
technology in 1984.20 It has since then evolved into applications involving the generation of large
arrays of molecules for molecular recognition against desired targets. The advantage of this
method is related to the use of a solid support, which facilitates chemical reactivity by adding an
excess of reagents, isolation of products bound to an insoluble support and separation of unwanted
materials that may be simply washed away by solvent filtration. As such, solid-phase synthesis
facilitates the rapid preparation of a library of molecules without having to perform step-wise
work-up and purification steps. Thus, solid-phase synthesis is the method of choice for the
preparation of lengthy and difficult peptide sequences for structure-activity relationship studies
with receptor targets.21
Solid-phase peptide synthesis has facilitated the rapid production of biologically active
sequences such as neurotransmitters, hormones, neuromodulators cell penetrating and targeting
peptides.22 At the cornerstone of its utility is an insoluble polymer support (typically polystyrene)
that facilitates the prerequisite peptide coupling and deprotection steps for assembling the
constituent amino acid building blocks into bio-active peptides (Figure 1.4). This iterative
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procedure is now automated and optimized under microwave irradiation.23 Following solid-phase
synthesis, peptides are cleaved from the solid-support, deprotected and purified/analyzed using
reverse-phase high performance liquid chromatography (RP-HPLC). As such, solid-phase peptide
synthesis has facilitated combinatorial peptide synthesis for a wide range of applications, including
those belonging to the cancer-targeting peptides as highlighted in Chapter 2 of this thesis.

Figure 1.4. Solid-phase peptide synthesis based on the Fmoc-protecting group strategy. An amino-derived
solid-support is coupled to an Fmoc-amino acid to generate the peptide bound support. Following peptide
coupling, Fmoc deprotection liberates the free amino group for continued cycles of coupling and
deprotection until the desired peptide has been synthesized on solid-phase.

1.2.2 PHAGE-DISPLAY PEPTIDE LIBRARY METHOD
Phage-display technology is an in vitro technique used for the expression of peptide ligands
from bacteriophages.24 Since this method enables the generation of 108-109 bacteriophages per
iterative round of in-vitro amplification and selection, a library of peptides for screening specific
interactions with proteins and other biomacromolecules (i.e. bio-panning) are rapidly generated.
Moreover, the expressed peptides are not limited in size or sequence composition, which are both
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challenges in solid-phase peptide synthesis. Since the peptides are expressed on the virion surface,
naturally occurring peptide folds that are typically responsible for peptide-protein interactions are
readily observed. However, these bio-panning methods are not amenable to the incorporation of
modified amino acids that may be crucial in improving the pharmacokinetic properties of the lead
peptide ligand.
In this method (Figure 1.5), genetically modified bacteriophages infect bacterial cells
which allows for recombinant DNA replication and expression with the host cell machinery. Once
replicated, the bacteriophages are programed to display the peptide library on their surface. This
is referred to as a phage-display peptide library, a heterogeneous mixture of phage clones carrying
different peptide sequences on its virion surface. The peptides in the phage-display library have
two main characteristics required for chemical evolution – reproducibility and mutations.
Introduction of mutations into the phage genome stimulates the expression of chemically diverse
peptide populations that were not expressed during the first rounds of amplification and selection.
The displayed peptides are then screened against receptor targets to determine the lead peptide
ligands.
Screening and selection of the phage-display peptide libraries is next accomplished by
standard affinity purification techniques. The target receptor is tethered to a solid support and the
phage mixture is passed over the immobilized receptor. The phages whose displayed peptides bind
to the receptor are captured on the surface allowing the unbound phages to be washed away. The
bound phages are then eluted into a solution which loosens the receptor-peptide bonds that yields
an eluant population of phages. These eluted phages are further amplified (106) by infecting fresh
bacterial cell hosts to produce new clones. The amino acid sequences of the peptides that bind to
the target receptors are then determined by sequencing the viral DNA and peptides. Peptides are

7

typically selected from libraries which express variants of 7 to 20 amino acids on the capsid protein
(pIII or pVIII) of the phages.

Figure 1.5. Phage-display bio-panning for the selection of cancer-targeting peptide ligands. Figure adapted
from Wu, H-C. et al J. Cancer Mol. 2006, 2, 57-66.28

Fruitful applications of phage display peptide bio-panning experiments includes the selection of a
16-mer peptide targeting the VEGF receptor on endothelial tumor tissues,25 peptides that bound to
the CD-21 B-cell Lymphoma cell surface marker26 and a 26-mer peptide that bound to FGF-R on
the surface of Sf-9 cells,27 among many others.19
1.2.3 OBOC COMBINATORIAL LIBRARY METHOD
OBOC combinatorial peptide library synthesis unleashes the power of synthetic chemistry
for the incorporation of chemical modification without restriction within bio-active sequences.19
8

Thus, peptide mimics (peptidomimetics) are crucial for improving the pharmacokinetic properties
of the native sequences, while facilitating structure-activity relationship studies with receptor
targets.29 These are fundamental requirements for an effective cancer-targeting strategy.
The OBOC combinatorial library is developed using a “split-mix” synthesis approach in
which each bead represents a unique chemical entity (peptide) for further diversification (Figure
1.6). This is the most common approach for synthetically making large peptide libraries (104-106)
prior to high-throughput screening with receptor targets for evaluating their biological activity.30

Figure 1.6. OBOC combinatorial library synthesis using the split-mix method. Figure adapted from Aina,
O.H.; et al Mol. Pharm. 2007, 4, 631-651.19

With large libraries of peptides in hand, encoding methods (tags) are used to keep track of
the individual peptide sequences on the beads.31 At the end of the synthesis, a dye is attached to
the target receptor which is washed across the polymer beads. A positive hit is identified when the
9

peptide bound bead adopts the color of the dye, and with growing color intensities validating tight
ligand binding to the target receptor (i.e. identification of a lead). The colored beads are then
selected and manually decoded to identify the chemical composition of the peptide sequence
(Figure 1.7).

Figure 1.7. OBOC Combinatorial Peptide Library Method. a) Orthogonal solid-phase synthesis of one
peptide per bead and b) Colorimetric detection of functionalized peptide bound to the solid support. Figure
adapted from Aina, O.H.; et al Mol. Pharm. 2007, 4, 631-651.19

The peptide library screening method may also be developed on living cells, to identify
ligands that bind to cell-surface receptors.16,19 This method can be applied to both suspension and
adherent cell cultures (specifically fresh cancer cells isolated from patient blood). This is
performed by incubating the cells with the beads under favorable growth conditions. The beads
with the appropriate ligands that bind to the cell surface receptors will be coated with a monolayer
of cells. Since there are hundreds of different macromolecules on the cell surface, it is reasonably
expected that some of the attachments are due to nonspecific binding and thus control experiments
are necessary. These include: a) recycling the beads for replicate cell binding experiments (Figure
1.8) and b) a dual-color screening method that can allow colorimetric detection of the peptide
ligands that have bound to the target cells (Figure 1.9).19
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Figure 1.8. Recycling peptide-bound beads for replicate cell adhesion studies. a) The beads initially coated
with the cancer cells are isolated and stripped by washing with 8 M guanidinium chloride and re-screened
screened against non-cancer cell types. (b) If the beads bind to these non-cancer cells they considered false
positives. Figure adapted from Aina, O.H.; et al Mol. Pharm. 2007, 4, 631-651.19

Figure 1.9. Dual-color screening methods involves tagging the cancer cells with a fluorophore (calcein
AM) and mixing them with unlabeled non-cancer cells prior to screening with the OBOC library. The beads
that only bind to the fluorescent cells are considered “true positive” beads and are isolated and retained.
Figure adapted from Aina, O.H.; et al Mol. Pharm. 2007, 4, 631-651.19

In this manner, the selection of potent cancer-targeting peptides armed with anti-cancer or
imaging agents were tested in cancer cell lines and tumor bearing animal models for applications
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in tumor-targeted detection and treatment. For example, the structure-function relationships of the
hybrid D-peptide sequence (kikmviswkg, HYD-1) on DU145 prostate cancer cells demonstrated
the ability to block the attachment of DU145 cells to anti-β1 antibody, fibronectin, laminin 1,
laminin 5, collagen IV and dermal fibroblasts. Inhibition of tumor cell adhesion to extracellular
matrix proteins and fibroblasts may halt human tumor cell progression and metastasis at distant
locations.32 Another example is associated with the selection of a high affinity peptidomimetic
ligand OA02, that targets activated α3β1 integrin overexpressed on the cell surface of ovarian
cancer. When conjugated with fluorescent dyes Cy5.5 or Alexa680, this peptide ligandfluorophore conjugate facilitated imaging of the α3 integrin receptor expressed in ovarian
adenocarcinoma xenografts in nude mice.33
There are several examples of OBOC combinatorial libraries used in the identification of
high-affinity peptide ligands for applications in cancer research.19 For the scope of our research,
we have focused on the identification of peptides that target and bind to cancer cells – cancer
targeting peptides.
1.3 MICROARRAY APPLICATIONS
The application of functionalized microarrays has facilitated the high-throughput peptide
library screening for the rapid determination of substrate-receptor binding interactions.34 This
screening method has been used to elucidate the binding site domain and the active site residues
responsible for high affinity and selective ligand-receptor interactions. Fluorogenic peptide ligands
are particularly useful in this application, as measurements in substrate-receptor binding affinity
(KD values) can be determined by fluorescence signaling and quantitative analyses. For example,
of the use of an oligonucleotide microarray was used to decode a library of peptide nucleic acid
(PNA)-fluorogenic substrates for the protease enzymes (Figure 1.10).35 In this assay an
12

oligonucleotide microarray is assembled on a glass slide and a combinatorial library of PNAs with
‘caged’ (inactive) fluorescent labels are added to the support-bound oligonucleotides.
Complementary PNA:oligonucleotide sequences will hybridize on the microarray. The
functionalized microarray is then incubated with protease enzymes (isolated or in cell lysates) and
the PNA substrates are identified by the release of the fluorescent signal following proteolytic
cleavage. Since the oligonucleotides are encoded within the microarray, sequence analyses of the
fluorescent ‘hits’ identifies the sequence of the PNA substrates. Quantitative analyses measuring
binding affinity (KD values) and inhibitory activity (IC50 values) may also be determined by the
intensity of the released fluorophore. These studies may be potentially useful in the identification
of lead peptide inhibitors for the extracellular matrix metalloproteinases that have been found to
contribute to the invasive behavior of malignant cancer cells.36

Figure 1.10. Oligonucleotide microarrays for profiling PNA:protease interactions. (a) Caged fluorescent
PNAs exhibit fluorescence signaling during proteolysis, and (b) Caged PNA substrates are added and
hybridized to an oligonucleotide microarray. Following administration of proteases, fluorescent signaling
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on the microarray identifies the location of a PNA substrate for the protease enzyme. Figure adapted from
Winssinger, N.; et al Chem. Biol. 2004, 11, 1351-1360.35

1.4 CHARACTERIZATION OF CTP ACTIVITY IN CANCER CELLS AND IN-VIVO
Following the identification of lead peptide ligands of cancer cell surface receptors, the
incorporation of imaging and therapeutic agents have respectively facilitated, the characterization
and anti-cancer activity of CTPs in cell lines and in-vivo. The 123I-labeled RGD peptide and related
analogs has been used for the development of integrin-αvβ3-targeted radiotracers in imaging
rapidly growing metastatic tumors in nude mice.37,38 Integrin-αvβ3 is overexpressed on the surface
of activated endothelial cells and cancer cells, and thus serves as a valuable bio-marker in this
tumor targeting approach. The radiotracers 123I, 18F, 86Y, 68Ga, and 64Cu with bifunctional DTPA,
DOTA, NOTA, FBOA, TETA, TE2A chelators have all been introduced within RGD
peptidomimetics for monitoring tumor angiogenesis in-vivo by molecular PET scan imaging
(Figure 1.11).38

Figure 1.11. PET scan images of nude mice bearing M21 melanoma cancer cells. Mice treated with
[cyclo(RGDfE)HEG]2-K)2-K-Dpr—[18F]FBOA identifies the location of high integrin-αvβ3 expression at
the localized tumor site. Figure adapted from Schottelisu, M.; et al Acc. Chem. Res. 2009, 42, 969-980.38
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There are several other cell surface receptors that have been selected and exploited in
tumor-targeting approaches.19 These include: HIF-1, type II TGF-β, and ErbB1, but for the scope
of our research we focused on the Glucose Regulated Protein 78 (GRP78). The GRP78 receptor,
is a 78 kDa member of the heat shock family of proteins which functions as an intracellular
chaperone in the lumen of the endoplasmic reticulum (ER). GRP78 activity is stimulated by the
unfolded protein response (UPR) under stress-induced conditions that are typically associated with
protein mis-folding events.39 GRP78 regulates additional intracellular signaling events that are
associated with embryonic development, aging, Ca2+ homeostasis and insulin/IGF-1 signal
transduction applicable to glucose metabolism, cell proliferation and anti-apoptosis.40 Moreover,
GRP78 is expressed in all cell types, where it chaperones protein folding activity in the ER, it
interacts with anti-apoptotic executors in the mitochondria and at the cell surface it directs cell
signaling.41
In cancer, GRP78 is over-expressed and cell surface localized, where it exhibits a variety
of signaling pathways which induce cancer initiation, proliferation and metastatic spread. 42
Significantly, GRP78 has been found on the surface of cancer cells but not in normal tissues,
thereby making it a valuable biomarker for cancer-targeting therapy approaches.40-43 Towards this
goal, cell surface GRP78 ligands, such as antibodies44 and short peptides derived from phage
display bio-panning experiments45 have been used to target tumors selectively for anti-cancer
activity. For example, Janda and co-workers have reported the phage display peptide library
selection of Pep42, a cyclic peptide, CTVALPGGYVRVC-CONH2, that specifically binds to the
GRP78 receptor, and internalizes into highly metastatic melanoma cells by receptor-mediated
endocytosis.46 Pep42 has been effectively conjugated with anti-cancer agents such as Taxol, and
the pro-apoptotic D-(KLAKLAK)2 sequence triggering programmed cell death specifically in
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cancer cell lines and in xenograft mouse models (Figure 1.12).46 Thus, the highly specific Pep42GRP78 ligand-receptor interaction forms the basis of my thesis objectives, leading towards the
development of new and improved drug delivery methods in cancer treatment.

Figure 1.12. Scanning confocal laser fluorescence microscopy images indicating the localization of FITClabeled Pep42 on the surface of highly GRP78 expressing melanoma cancer cells. 46a Figure adapted from
Kim, Y. et al Biochemistry 2006, 45, 9434.

1.5 THESIS OBJECTIVES
In hepatoblastoma HepG2 liver cancer cells, GRP78 overexpression was found to play a
pivotal role in venous tumor invasion resulting in resistance and metastasis, while underscoring an
unmet need to develop more effective treatment methods.41 Towards this goal, we43b along with
others47 have demonstrated that targeting GRP78 overexpression with siRNAs in HepG2 liver
cancer cells produce significant GRP78 silencing effects (60-87%), modest cancer cell deaths (~510%) and abolished signaling activity for viral entry and infection.47 Thus, HepG2 cancer cells are
clinically relevant tumors for validating our proposed GRP78-targeting strategy.
Towards this ultimate goal, Chapter 2 of this thesis describes the optimized Fmoc-solid
phase peptide synthesis of a small library of GRP78-targeting CTPs possessing poly(D/L-Arg)
16

sequences. The synthetic strategy features an optimization study which compares the influence of
the solid-support on peptide synthesis efficiency. Methods for peptide synthesis, LC/MS analyses
and purifications are outlined in this chapter.
With pure peptides in hand, structural investigations exploring the potential influence of
peptide secondary structures on biological activity was next accomplished. Chapter 3 of this thesis
highlights methods in circular dichroism (CD) structural analyses of the CTP sequences.
Specifically, the effect of the varying lengths and changes in stereochemistry of the poly(D/L-Arg)
sequences on CTP structure and stability were scrutinized.
In order to elucidate the relationship between peptide structure and biologically activity,
HepG2 liver cancer cells were cultured as a model and clinically relevant cell line for our GRP78
targeting strategy. Chapter 4 of this thesis highlights peptide biological activity. In collaboration
with Dr. Allan D. Blake and students Anthony Maina, Christopher Parronchi, Brittany Blackman
Megan Kelly and Mariana Phillips peptides were examined for their biological activity in HepG2
cells and as siRNA delivery agents. These studies are crucial for the development and application
of CTPs in our GRP78-targeting approach.
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CHAPTER
2:
SYNTHESIS
AND
CHARACTERIZATION
POLY(ARGININE) DERIVED CANCER-TARGETING PEPTIDES

OF

2.1 ABSTRACT
The solid-phase synthesis and characterization of a new library (16) of GRP78 cancertargeting peptides possessing varying lengths (0-12) of poly(D/L-Arg) sequences have been
synthesized, purified and analyzed by LC/MS in this chapter. These peptides are based on the
highly specific Pep42 cyclic sequence, H2N-CTVALPGGYVRVC-CONH2, which has been
shown to target the Glucose-Regulated Protein 78 (GRP78) receptors over-expressed on the cell
surface of cancer cells. In this study, Pep42 derived poly(arginine) peptides were effectively
synthesized by Fmoc-based solid-phase peptide synthesis (SPPS). The use of various Rink amidelinker resins based on the polystyrene-divinylbenzene (PS-DVB), polystyrene-graftedpoly(ethylene glycol) (TentaGel) and poly(ethylene glycol) (NovaPEG) were explored to optimize
the SPPS method. Peptide sequences prepared on a hydrophilic (NovaPEG) resin ultimately
provided the best results, generating good yields (12-46%) and crude purities >90% following
LC/MS analyses. These sequences were further purified by RP-HPLC methods to increase purities
(>95%) in preparation for structural, biophysical studies (Chapter 3) and biology (Chapter 4).

2.2 INTRODUCTION
2.2.1 RATIONAL DESIGN OF POLY(ARGININE) DERIVED PEP42 SEQUENCES
As highlighted in Chapter 1, the screening of phage display peptide libraries against tumor
cells has isolated a peptide ligand that binds specifically and with high affinity to cell surface
GRP78.1 The GRP78 receptor is localized on the cell surface of cancer cells and not on healthy
ones making it a viable biomarker for the development of cancer-targeting approaches.2 Towards
this goal, the Pep42 ligand, corresponding to a cyclic 13-mer sequence, namely H2NCTVALPGGYVRVC-CONH2, 7, was found to bind to GRP78 and internalize anti-cancer drugs
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within tumor cells for more potent and selective cancer cell death relative to the administration of
anti-cancer drugs without Pep42.1
Arginine-rich peptides are a class of cell-permeable peptides that possess the ability to bind to
negatively charged bio-molecules, such as the short-interfering RNA (siRNA) and facilitate their
cell translocation for RNA interference (RNAi) activity.3 Moreover, there has been a correlation
between cell permeability and the increase in the number of arginine residues (6-12) which elicit
optimal translocation activity.4 Although arginine-rich peptides are highly efficient in mediating
in vitro cellular uptake of siRNA for bio-activity, their in vivo application has been limited by poor
specificity, as these peptides are dispersed in almost all cell types.5
Thus, combining the tumor-homing capabilities of Pep42, with the poly-arginine sequences
known to facilitate siRNA delivery for RNAi activity forms the basis of our new GRP78-targeting
gene therapy approach. These two properties produces a drug delivery vehicle that possesses the
ability to seek and destroy cancer cells (Figure 2.1), with a selectivity that is absent in traditional
chemotherapy or radiation treatments. Therefore, our proposed cancer-targeted gene therapy
approach aims to produce and new and improved form of cancer therapy.

Figure 2.1. Rational design of CTPs synthesized and characterized in this study.

2.2.2 SOLID PHASE PEPTIDE SYNTHESIS (SPPS) METHOD
The solid phase peptide synthesis (SPPS) method has emerged as the method of choice for
the rapid production of short (3-5) to medium (20-30) length peptides. The use of an insoluble
23

polymer support has replaced the solution phase synthesis of peptides. These methods circumvent
the need for laborious reaction, work-up and purification steps following each coupling and
deprotection procedure.6 SPPS was pioneered by Bruce Merrifield, who first reported the synthesis
of a model tetrapeptide (LAGV) on a polymer bead and was later awarded the Noble prize in
Chemistry (1984) for his discovery.7 SPPS has since then unleashed a wide range of natural and
un-natural peptides for applications in biology, chemistry and therapy. In this chapter, methods for
SPPS are highlighted and specifically applied to the production of a new class of poly(arginine)
cancer-targeting peptides.
Fmoc-SPPS has emerged as the solid phase method of choice for the production of
peptides. This strategy features the use of a fluorenylmethyloxycarbonyl (Fmoc) protecting group
at the N-terminus of the amino acid in order to facilitate its introduction into the SPPS procedure.8
The first step involves the selection of a suitable polymer support (resin) for the synthesis of the
desired peptide sequence. Historically, the Merrifield resin was employed in the synthesis of short
sequences that did not require side-chain protecting groups.7 The Merrifield resin is composed of
a polystyrene-divinylbenzene (PS-DVB) cross-linked core (Figure 2.2A) and a suitable linker for
the production of peptide acids9 and amides.10 For the preparation of lengthier and more
challenging hydrophobic sequences that are prone to aggregation which diminishes the synthesis
efficiency more polar solid-supports have been produced. Resins that have greater swelling
tendencies in polar aprotic solvents such as DMF, the solvent of choice in the SPPS procedure
have been developed. For example, the amphiphilic polystyrene-graft-poly(ethylene glycol) resin
(TentaGel, Figure 2.2B),11 has been used in the solid-phase synthesis of difficult peptide
sequences, including peptoids and fluorescently labeled peptides. Recently, a polar poly(ethylene
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glycol) (NovaPEG, Figure 2.2C)12 resin has been developed for the efficient preparation of
challenging hydrophobic peptides such as the beta-amyloid (1-42).

Figure 2.2. Three different resins for Fmoc-SPPS: A) Rink amide-linker polystyrene-divinylbenzene (PSDVB) B) Rink amide-linker amphiphilic polystyrene-graft-poly(ethylene glycol) resin (TentaGel), and C)
poly(ethylene glycol) (NovaPEG).

Following the judicious selection of an insoluble polymer support, the coupling of the NFmoc amino acid to the solid support is effected by a coupling reagent. The coupling reagent
typically functions to convert the C-terminal carboxylic acid to a reactive ester which favors
coupling to the amino (peptide amides) or hydroxyl (peptide acids) groups on the solid support.
Moreover, coupling reagents also facilitate the key peptide bond forming reactions between the Nterminal peptide bound support and the C-terminal active ester of the coupling N-Fmoc amino
acid. Many coupling reagents for SPPS have been reported in the literature,13 among the most
useful are the carbodiimide-based couplings. In this case, N,N’-diisopropylcarbodiimide (DIC) and
1-hydroxybenzotriazole (HOBt) have been used for the efficient Fmoc-SPPS of a 51-mer peptide
bearing the main heparin binding site (60-110) of human pleiotrophin (hPTN).14 The total synthesis
of hPTN was assisted with microwave (MW) radiation, which allowed completion of the MW-
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SPPS procedure in 30 hours. This optimized method produced the desired peptide in 51% crude
yield and >99% purities following RP-HPLC purification. More reactive coupling reagents have
been developed, particularly based on the uronium coupling agents. For instance, O-(1H-6chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) worked
particularly well in the solid phase synthesis of challenging peptides with coupling times as short
as 1 minute.15
The coupling procedure is followed by an Fmoc deprotection step, in which a secondary
alkylamine is used to effect the elimination of the Fmoc group without concomitant epimerization
of the peptide-bound support. Towards this goal, dilute solutions of alkylamines (i.e. 20%
piperidine in DMF or 10% piperidine in EtOH/NMP, 10:90 v/v) have been used to generate the
fully optimized Fmoc-SPPS (Figure 2.3) procedure of a variety of peptide and peptidomimetic
sequences. The modern Fmoc-SPPS method is automated and optimized with microwave heating
to effect rapid and high yielding coupling and deprotection steps.16 Following synthesis, peptide
cleavage from the solid support and deprotection of side-chain protecting groups are typically
accomplished with concentrated trifluoroacetic acid (TFA) with minimal addition (<5%) of
reaction scavengers (i.e. H2O, triethylsilane, phenol). These conditions minimize side-product
formation and yields the crude peptide in solution for analysis and purification. Thus, the FmocSPPS method is the method of choice for the production of the poly(arginine) derived Pep42
sequences described in this chapter (Table 2.1).
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Figure 2.3. Fmoc-Solid Phase Peptide Synthesis (SPPS) method.

2.3 CHAPTER OBJECTIVES
The main objective of this thesis chapter involves the production of an optimal Fmoc-SPPS
method for the preparation of the Pep42-poly(arginine) sequences. This optimization procedure
studies the influence of the resin on peptide synthesis efficiency. In this study, the non-polar PSDVB resin was compared to the amphipathic Tentagel and polar NovaPEG resins to determine
which solid support fares best in the synthesis procedure. The efficiency of the SPPS method was
determined by the peptide % yield recovery and the crude % purity. Following peptide purification
by RP-HPLC and characterization by LC/MS, samples were ready for follow-up studies exploring
peptide structure, biophysical and biological properties (Chapters 3 and 4).
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2.4 RESULTS AND DISCUSSION
2.4.1. FMOC-SPPS OF PEP42-POLY(ARGININE) SEQUENCES
The first aim of this study was to synthesize the peptides in the highest yields and purities.17
To achieve this goal, Fmoc-SPPS conditions were initially optimized for the hydrophobic Pep42
CTP sequence: H2N-CTVALPGGYVRVC-CONH2, 2.1,1 (Figure 2.4A) on a conventional Rink
amide-linker Merrifield resin, consisting of a polystyrene-divinylbenzene (PS-DVB) cross-linked
core11 (Figure 2.3A). Under these conditions Pep42 crude purities of only 28% was achieved upon
analysis by RP-HPLC, (Figure 2.4B) indicating that the Fmoc-SPPS conditions with the PS-DVB
resin required improvement for the production of Pep42 (Table 2.1, sequence 2.1).
In an attempt to improve Pep42 synthesis efficiency, the influence of the solid support on
peptide synthesis was next explored. Specifically, the use of more polar resins relative to the PSDVB support produced encouraging results in related hydrophobic sequences.11,12,18 The success
of solid phase peptide synthesis is strongly related to the solid support chosen and its performance.
Using the mole ratio of 1:3:3:6 of resin:Fmoc-amino acid:HCTU:NMM in DMF there should be a
balance between the swelling and loading capabilities when choosing a type of resin. Since there
is no general rule to decide which type of resin should be used, we considered several properties
such as swelling-solvent ratio, length of the desired sequences and the hydrophobicity of the
sequence. With lower resin loadings on the more hydrophilic resins such as the NovaPEG, increase
swelling properties have been found in DMF leading to enhanced synthesis efficiencies. 12
Conversely, on the higher loading hydrophobic polystyrene resins, less swelling was noticed in
DMF which lead to a decrease in synthetic efficiency. Thus, CTP 2.1 was equally prepared on a
Rink amide-linker amphiphilic polystyrene-graft-poly(ethylene glycol) (TentaGel)11 and
hydrophilic poly(ethylene glycol) (NovaPEG)12 based solid supports (Figure 2.3, B and C) in
order to explore the influence of the solid support on peptide synthesis. In these cases, peptide
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crude purities improved from 28% on a PS-DVB support, to 67% on Tentagel S RAM resin
(Figure 2.4C) and ultimately to 93% on a poly(ethylene glycol) Rink Amide NovaPEG resin
(Figure 2.4D). Isolated yields of 14% (15 mg) were recovered for Pep42 on a NovaPEG resin,
illustrating sufficient peptide recovery for structure, biophysical and biological studies (Chapters
3 and 4).
With optimized conditions for the synthesis of CTP 2.1, poly(arginine) derived Pep42, 2.2,
containing a tri(arginine) sequence at the C-terminus was made on the Tentagel and NovaPEG
resins. The use of more polar solid supports had been reported in the literature to improve synthesis
yields and purities of poly(Arg) sequences.18 In the case of Pep42-R3, 2.2, an increase in the
polarity of the solid support resulted in greater peptide crude purities (69% to 98%) with the
Tentagel S RAM and NovaPEG resins, respectively (Table 2.1). The unique composition of the
NovaPEG polymer matrix affords excellent swelling capabilities in polar aprotic solvents that are
commonly used in the SPPS method (i.e. DMF or NMP). This feature increases the surface area
for reaction on solid phase producing peptides of high quality.12,18 This is particularly useful in the
preparation of amphiphilic sequences such as the Pep42-poly(arginine) series. Similar amphipathic
peptides have been shown to aggregate during the course of the SPPS method resulting in
diminished yields and purities.12,16-18 Moreover, poly(arginine) sequences have been particularly
difficult to synthesize by conventional Fmoc-SPPS. This is reportedly due to the high steric
hindrance and difficulty in deprotection of the arginine side-chain Pbf protecting groups in addition
to pre-mature cleavage from the solid support that results from δ-lactam formation (Figure
2.5).18,19 In spite of these hurdles, good synthesis efficiencies (crude purities 93-98%) and
recoveries (14-46%) were obtained for the Pep42-poly(arginine) series on a NovaPEG resin
(Table 2.1), underscoring the importance of the resin in the synthesis of challenging sequences.
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Figure 2.4. Synthesis and characterization of Pep42, (Table 2.1, sequence 2.1) A) Fmoc-based Solid Phase Peptide
Synthesis and RP-HPLC chromatograms at 214 nm on Rink Amide B) Merrifield C) TentaGel and D) NovaPEG resins.
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With the synthesis condition optimized for the Pep42-poly(L-agrinine) series (Table 2.1,
sequences 2.2-2.5) we synthesized a series of Pep42-poly(D-arginine) sequences (Table 2.1,
sequences 2.6-2.9) using the same conditions. This Pep42-poly(D-arginine) series was synthesized
in order to investigate their stability versus that of the Pep42-poly(L-arginine) series. It is also
worthwhile to note that similar synthesis efficiencies (crude purities 86->95%) and recoveries (1837%) were observed for the Pep42-poly(D-arginine) series (Table 2.1, sequences 2.6-2.9). These
peptide sequences were synthesized using conventional Fmoc-SPPS on a hydrophilic NovaPEG
resin with conditions that were optimized for the Pep42-poly(Arg) series. This highlights the
method’s ability to incorporate un-natural amino acids that may ultimately improve peptide
pharmacokinetic properties.20

Figure 2.5. Intramolecular cyclization of arginine to the resulting δ-lactam.18,19 Figure adapted from GarciaRamos, Y. et al J. Pept. Sci. 2010, 16, 675.

In the cleavage and deprotection step we used TFA as the side chain protecting groups of
the amino acids are acid labile. This cleavage and deprotection mixture contained TES which acts
as a scavenger preventing any side reactions as the protecting groups are being removed ensuring
that the desired peptide sequence is intact. The final step following peptide cleavage and
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deprotection from the solid support involves the oxidation of the cysteinyl residues to the cyclic
disulfide-linked peptides. Recent studies have shown that there is no internalization of the linear
reduced form of Pep42 (Table 2.1 sequence 2.1) within cancer cells, demonstrating that the cyclic
constraint is a crucial structural element for Pep42 cellular binding and internalization.1 There are
various oxidation techniques for the formation of disulfide bonds in peptides and proteins. These
include: Ellman’s reagent: 5,5ʹ-dithiobis(2-nitrobenzoic acid),21 potassium ferricyanide,22 iodine23
and DMSO,24 in addition to air oxidation, which involves bubbling a stream of air into the
cleavage cocktail.25 The latter air oxidation method was used in the cyclization step of the Pep42poly(arginine) sequences synthesized in this study (Table 2.1). To evaluate the drug delivery
capabilities of CTPs (Table 2.1, sequences 2.1-2.9) within cell-based assays, CTPs were
fluorescently tagged with fluorescein isothiocyanate (FITC).26 The FITC fluorophore (λabs: 494
nm and λem: 521 nm) was introduced at the N-terminus of the CTP sequences to minimize its
influence on the biological activity of the peptides. FITC can also react with the sulfhydryl groups
of reduced cysteines and the ɛ-amino of lysines27 resulting in unwanted side-reactions and with
the N-terminal residue leading to its deletion from the sequence (Figure 2.6).28 This reaction
follows the Edman degradation pathway affording a fluorescent thiohydantoin (FTH) from the last
α-amino acid of the peptide sequence. This reaction can be avoided by introduction of a non-α
amino acid spacer between thiourea bond and the peptide. Therefore, an aminohexanoic acid (εAhx) spacer was added to inhibit these side-reactions and lead to the formation of stable FITClabeled sequences (Table 2.1, sequences 2.10-2.15).26
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Figure 2.6. FITC-cleavage of the N-terminal residue of the peptide bound to the solid support.

2.4.2 ANALYSIS AND PURIFICATION OF PEP42-POLY(ARGININE) SEQUENCES BY
LC/MS
Following synthesis of this small library of synthetic peptides (2.1-2.15), their purities were
determined by RP-HPLC and identities ascertained by molecular weight analyses using LC/MS.
The use of an octadecyl (C18) reverse-phase column, packed with 60 Å pore size silica was found
to be perfectly suitable for the HPLC analyses of the synthetic peptides.29 Considering the synthetic
peptides vary in length of the poly(Arg) sequences (0-12 residues), the Pep42-poly(arginine) series
were found to exhibit a wide range of polarities which influenced solubility, analyses and
separation. For example, the Pep42 sequence was found to be rather hydrophobic in comparison
to those derived with the poly(Arg) sequences. This is particularly due to the multiple non-polar
(Val, Ala, Leu, Ile and Tyr) residues which diminished water solubility. In contrast, peptides with
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increasing poly(Arg) sequences (3-12) enhanced water solubility while also maintaining solubility
in organic solvents such as MeOH and MeCN. In all cases, peptide samples were prepared in a
combination of H2O:MeOH or MeCN (50:50 v/v, 1.0 mL) with minimal addition of an ion-pairing
reagent (0.1% TFA or FA) to enhance dissolution for RP-HPLC analyses. RP-HPLC of the
peptides (Table 2.1, sequences 2.1-2.14) was established with a gradient method of MeCN-H2O
and MeOH-H2O (2-82%, 1.0 mL/min, 18 min) with TFA (0.1%) as acidic ion pairing reagent that
provided the best resolution of the crude peptide samples in combination with H2O:MeCN (Figure
2.7). The peak purities of the peptide sequences were monitored at 214 nm with a photodiode array
(PDA) detector. This wavelength is characteristic of the amide bond absorption which provides
the most accurate quantitative determination of peptide purities during analyses.30 This is because
all peptides are composed of the same peptide backbone, thereby making the analyses not sequence
specific and also not contingent on the eluent system (λMeOH: 205 nm and λMeCN: 190 nm). With
these conditions, peptides were analyzed with good crude purities (>90%) following SPPS and the
post-synthesis work-up procedures (Table 2.1).
Considering peptide purity is of paramount importance for structure-activity relationship
studies (Chapter 3 and 4), semi-preparative RP-HPLC was next accomplished (YMC-Pack ODSA C18 column 20 x 250 mm, 5.0 µm particle size). Peptide samples were recovered from the
purifications, and analyzed by LC/MS to validate peptide purity (>95%) and identity by molecular
weight confirmation. For the latter, ESI-MS was selected as the method of choice for peptide
characterization.31 ESI-MS is a mild ionization method producing minimal fragmentation during
the analyses. In the case of the Pep42-poly(arginine) sequences, the desired molecular weights
were observed as mass:charge (m/z) ratios that were contingent on the number of charged arginine
residues found within the sequences (Table 2.1).
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A

B

Figure 2.7. Representative RP-HPLC chromatograms of purified Pep42-R9 (Table 2.1, sequence 2.4)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Moreover, peptide purities (>95%) were confirmed in different eluent systems (2-82%
MeOH/H2O with 0.1% FA or MeCN/H2O with 0.1% TFA over 18 min) which produced different
retention times for the peptide samples while maintaining the desired peptide purity. The samples
were then lyophilized to remove the residual acid and stored as dry white powders at -20 °C. It is
also worthwhile to note that different retention times, albeit with the same chromatographic
conditions, were observed between the Pep42-poly(L- and D-arginine) series. These results were
consistent with those observed for diastereomeric mixtures of peptides or samples that analyzed
peptide diastereomers by RP-LC/MS.32 In our case, the Pep42-poly(L- and D-arginine) sequences
were separately synthesized in good yields (12-46%) and isolated in purities (>95%) for structureactivity relationship studies. More specifically, D-peptides have been shown to improve peptide
pharmacokinetic properties for applications in biology.33
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Table 2.1. Characterization data for the peptides synthesized in this study.
a

Entry

b

Sequence

Crude
Purity (%)

Isolated
Purity (%)

2.1

CTVALPGGYVRVC

93

2.2

CTVALPGGYVRVC-R3

2.3

c

d

Isolated
Yield
(%/mg)

M.W.
(g/mol)

99(98)

14/12.2

98

99(99)

CTVALPGGYVRVC-R6

97

2.4

CTVALPGGYVRVC-R9

2.5

e

f

g

Z

RT
(min)

RT
(min)

667.9 (667.8)

2

11.2

9.4

23/14.9

601.8 (601.6)

3

8.1

8.4

98(98)

46/24.8

1136.5 (1136.8)

2

8.4

8.6

93

98(98)

15/9.2

548.6 (548.7)

5

8.2

8.7

CTVALPGGYVRVC-R12

94

97(96)

29/16.7

803.0 (803.2)

4

7.2

8.0

2.6

CTVALPGGYVRVC-r3

86

98(96)

25/19.4

601.8 (601.6)

3

9.1

8.3

2.7

CTVALPGGYVRVC-r6

>95*

>95(>95)

37/23.6

758.1 (758.2)

3

9.7

8.1

2.8

CTVALPGGYVRVC-r9

86

98(96)

18/12.3

549.1 (548.7)

5

7.7

8.2

2.9

CTVALPGGYVRVC-r12

95

96(97)

21/19.3

802.9 (803.2)

4

8.2

5.4

2.10

FITC-Ahx-CTVALPGGYVRVC

95

95(95)

24/15.2

451.9 (452.1)

4

8.7

11.4

2.11

FITC-Ahx-CTVALPGGYVRVC-R3

93

99(95)

15/9.7

603.3(602.9)

3

13.8

12.9

2.12

FITC-Ahx-CTVALPGGYVRVC-R6

98*

98(96)

13/10.2

568.5 (568.9)

4

8.7

9.1

2.13

FITC-Ahx-CTVALPGGYVRVC-R9

93

98(96)

12/9.6

549.5 (549.6)

5

11.7

10.1

89

96(95)

15/12.0

642.8 (643.0)

5

9.6

9.9

2.14

FITC-Ahx-CTVALPGGYVRVC-R12

2.15

FITC-Ahx-R9

>95

99 (97)

21/17.4

474.0 (474.3)

4

8.1

8.8

2.16

R9

>95

99(95)

35/23.1

475.0 (475.2)

3

4.9

7.2

a

Crude purities by RP-HPLC at 214 nm using 2-82% MeCN/H2O with 0.1% TFA over 18 min. bIsolated purities by RP-HPLC at 214 nm
using 2-82% MeCN(MeOH)/H2O with 0.1% TFA(FA) over 18 min cIsolated yields based on the resin loading. dObserved mass (expected
mass) as [M+H]+/Z as detected by LCMS. eCharged state of the peptides as detected by LCMS in positive mode. fRetention times using
2-82% MeOH/H2O (0.1% FA) over 18 min. gRetention times using 2-82% MeCN/H2O (0.1% TFA) over 18 min.
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2.5 CONCLUSIONS
The design, synthesis and characterization of a novel class of poly(arginine) bearing
cancer-targeting peptides are described in this chapter. The rational design of the peptides was
based on the Pep42 sequence, discovered as a high affinity and selective ligand for the GRP78 cell
surface tumor antigen by phage display bio-panning selection.1 This cancer-targeting domain was
extended with varying lengths of poly(D- and L-arginine) sequences to explore the influence of the
poly(arginine) on structure, biophysical properties (Chapter 3) and biological activity (Chapter 4).
In this study, a small library of cancer-targeting peptides (16) derived from the Pep42poly(arginine) series were effectively prepared by Fmoc-SPPS. During the optimization studies,
the use of a polar, poly(ethylene glycol)-based resin (NovaPEG) provided the best results in the
synthesis of the desired peptide sequences. These optimization studies underscored the importance
of the solid-support in peptide synthesis efficiency. With an optimized protocol in hand, peptides
were obtained in good yields (12-46%) and purities (>95%) following RP-LC/MS analyses and
separations. The use of ESI-MS proved instrumental to the characterization of the peptide
sequences by molecular weight confirmation. The newly synthesized peptides may function as
useful probes for evaluating structure-function relationships with clinically relevant receptor
targets (Chapters 3 and 4).
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2.7 EXPERIMENTAL SECTION
2.7.1. MATERIALS
Protected amino acids Fmoc-Arg(Pbf), Fmoc-Cys(Trt), Fmoc-Val, Fmoc-Gly, Fmoc-Tyr(t-Bu),
Fmoc-Pro, Fmoc-Leu, Fmoc-Thr(t-Bu), Fmoc-Ala, Fmoc-ε-Ahx constituted the building blocks
for making the desired peptide sequences and were purchased from Novabiochem (San Diego,
CA). Peptide sequences were fluorescently tagged with FITC from Advanced ChemTech
(Louisville, KY). Peptide syntheses were conducted on hydrophilic poly(ethylene glycol)
(NovaPEG)12 Novabiochem (San Diego, CA), Tentagel S RAM, Rapp Polymere11 (Tuebingen,
Germany) and Polystyrene Rink Amide,10 Advanced ChemTech (Louisville, KY) resins.
Trifluoroacetic acid (Biograde) was purchased from VWR (Radnor, PA), N,N-dimethylformamide
(BioAnalyzed) was obtained from J.T. Baker (St. Loiusville, KY), HCTU was from Advanced
ChemTech (Louisville, KY), N-methylmorpholine, piperidine and triethylsilane, acetonitrile and
dichloromethane were all purchased from Aldrich (Milwaukee, WI) and used without further
purification. HPLC grade methanol and acetonitrile were purchased from Aldrich (Milwaukee,
WI).

2.7.2. PEPTIDES SYNTHESIS
All peptides were prepared by stepwise solid-phase synthesis protocols using Fmoc chemistry15
on a PSI 200C peptide synthesizer (Fairfield, NJ), which included coupling of Fmoc-amino acids
(300 mol%, 3 eq.), on a hydrophilic poly(ethylene glycol) (NovaPEG)12 solid support (100 mg, 0.1
mmol) for 20 minutes using [2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium
hexafluorophosphate] HCTU (72 mg, 300 mol%, 3 eq.), N-methylmorpholine, NMM (34 µL, 600
mol%, 6 eq. ) in DMF (4.0 mL). The Fmoc deprotections (10 min) were repeated twice, by passing
a solution of 20% piperidine in DMF (4.0 mL) into the reaction vessels containing peptide-bound
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resin. Peptide coupling and Fmoc-deprotection reactions were repeated until the desired CTP
sequences reached completion. The Fmoc-ε-aminohexanoic acid (Ahx) was then coupled to CTPs
(Table 2.1, sequences 2.10-2.15, followed by Fmoc deprotection and coupling with fluorescein
isothiocyanate (FITC). FITC (9.68 µmol, 2 eq.) coupling was performed in pyridine/DMF/DCM
(12:7:5, 500 µL) overnight at room temperature (22 oC). Following synthesis, all peptides were
cleaved from the solid support and side-chain protecting groups removed using a mixture of
trifluoroacetic acid: triethylsilane: water (TFA:TES:H2O, 95:2.5:2.5 v/v/v, 3.0 mL) for 4 hours.
The peptides were concentrated to a viscous oil, precipitated in cold ether, and isolated as a white
pellet upon centrifugation. Following removal of the supernatant, the crude peptides were
dissolved in water and analyzed for purity. RP-HPLC was performed on a Waters 2695 Alliance
Separations Module equipped with a Waters 2998 Photodiode Array (PDA) detector employing
binary gradients of solvents A and B, where A is 0.1% TFA in water and B is 0.1% TFA in
spectrophotometric grade acetonitrile. Analytical RP-HPLC was performed using a Zorbax RXC18 column (4.6 x 250 mm, 5.0 µm particle size) set at a temperature of 25 oC and at a flow rate
of 1.0 mL/min, during a linear gradient 2-82% B over 18 min with detection at 214 nm. In all
cases, pure fractions (10.0 µL) were characterized on an Agilent 1100 Series ESI-LCMS with
single quadropole mass analyzer for molecular weight confirmation using LC conditions
previously described. Samples were purified on Waters 600 Alliance Separations Module
equipped with a Waters 2489 Photodiode Array (PDA) detector employing binary gradients of
solvents A and B, where A is 2.5% MeOH/0.1% FA in water and B is 0.1% FA in
spectrophotometric grade methanol. Crude samples were dissolved in 1.0 mL purified water,
filtered using PVDF (0.45 µm) and injected for purification. Preparative RP-HPLC was performed
using a YMC-Pack ODS-A C18 column (20 x 250 mm, 5.0 µm particle size) set at a temperature
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of 25 oC and at a flow rate of 15 mL/min, during a linear gradient 2-82% B over 18 min with dual
detection at 214 nm and 280 nm. Eluants collected after purification were lyophilized to a white
solid, re-dissolved in water and analyzed by LCMS to confirm identity and purity.

2.7.3 CHARACTERIZATION DATA
H2N-CTVALPGGYVRVC-CONH2 (Table 2.1, sequence 2.1). ESI-LCMS [2-82% MeOH in H2O
(0.1% FA), 18 min] RT = 11.2 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 9.4 min;
Calculated for C58H96N16O16S2 [M+2H]2+ 667.8 found m/z 667.9

H2N-CTVALPGGYVRVC-R3-CONH2 (Table 2.1, sequence 2.2). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 8.1 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.4
min; Calculated for C76H132N28O19S2 [M+3H]3+ 601.6 found m/z 601.8

H2N-CTVALPGGYVRVC-R6-CONH2 (Table 2.1, sequence 2.3). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 8.4 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.6
min; Calculated for C94H168N40O22S2 [M+2H]2+ 601.6 found m/z 601.8

H2N-CTVALPGGYVRVC-R9-CONH2 (Table 2.1, sequence 2.4). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 8.2 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.7
min; Calculated for C112H204N52O25S2 [M+5H]5+ 548.7 found m/z 548.6

H2N-CTVALPGGYVRVC-R12-CONH2 (Table 2.1, sequence 2.5). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 7.2 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.0
min; Calculated for C130H240N64O28S2 [M+4H]4+ 803.2 found m/z 803.0

H2N-CTVALPGGYVRVC-r3-CONH2 (Table 2.1, sequence 2.6). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 9.1 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.3
min; Calculated for C76H132N28O19S2 [M+3H]3+ 601.6 found m/z 601.8
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H2N-CTVALPGGYVRVC-r6-CONH2 (Table 2.1, sequence 2.7). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 9.7 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.1
min; Calculated for C94H168N40O22S2 [M+3H]3+ 758.2 found m/z 758.1

H2N-CTVALPGGYVRVC-r9-CONH2 (Table 2.1, sequence 2.8. ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 7.7 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.2
min; Calculated for C112H204N52O25S2 [M+5H]5+ 548.7 found m/z 549.1

H2N-CTVALPGGYVRVC-R12-CONH2 (Table 2.1, sequence 2.9). ESI-LCMS [2-82% MeOH in
H2O (0.1% FA), 18 min] RT = 8.2 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 5.4
min; Calculated for C130H240N64O28S2 [M+4H]4+ 803.2 found m/z 802.9

FITC-Ahx-CTVALPGGYVRVC-CONH2 (Table 2.1, sequence 2.10). ESI-LCMS [2-82% MeOH
in H2O (0.1% FA), 18 min] RT = 8.7 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 11.4
min; Calculated for C85H118N18O22S3 [M+4H]4+ 452.1 found m/z 451.9

FITC-Ahx-CTVALPGGYVRVC-R3-CONH2 (Table 2.1, sequence 2.11). ESI-LCMS [2-82%
MeOH in H2O (0.1% FA), 18 min] RT = 13.8 min; [2-82% MeCN in H2O (0.1% TFA), 18 min]
RT = 12.9 min; Calculated for C103H154N30O25S3 [M+3H]3+ 602.9 found m/z 603.3

FITC-Ahx-CTVALPGGYVRVC-R6-CONH2 (Table 2.1, sequence 2.12). ESI-LCMS [2-82%
MeOH in H2O (0.1% FA), 18 min] RT = 8.7 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT
= 9.1 min; Calculated for C121H190N42O28S3 [M+4H]4+ 568.9 found m/z 568.5

FITC-Ahx-CTVALPGGYVRVC-R9-CONH2 (Table 2.1, sequence 2.13). ESI-LCMS [2-82%
MeOH in H2O (0.1% FA), 18 min] RT = 11.7 min; [2-82% MeCN in H2O (0.1% TFA), 18 min]
RT = 10.1 min; Calculated for C139H226N54O31S3 [M+5H]5+ 549.6 found m/z 549.5
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FITC-Ahx-CTVALPGGYVRVC-R12-CONH2 (Table 2.1, sequence 2.14). ESI-LCMS [2-82%
MeOH in H2O (0.1% FA), 18 min] RT = 9.6 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT
= 9.9 min; Calculated for C157H262N66O34S3 [M+5H]5+ 643.0 found m/z 642.8

FITC-Ahx-R9-CONH2 (Table 2.1, sequence 2.15). ESI-LCMS [2-82% MeOH in H2O (0.1% FA),
18 min] RT = 8.1 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 8.8 min; Calculated for
C81H132N38O16S [M+4H]4+ 474.3 found m/z 474.0

H2N-R9-CONH2 (Table 2.1, sequence 2.16). ESI-LCMS [2-82% MeOH in H2O (0.1% FA), 18
min] RT = 4.9 min; [2-82% MeCN in H2O (0.1% TFA), 18 min] RT = 7.2 min; Calculated for
C54H110N36O10 [M+3H]3+ 475.2 found m/z 475.0
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CHAPTER 3: STRUCTURAL STUDIES AND THERMAL STABILITIES OF
THE Pep42-(POLY)ARGININE SEQUENCES USING CD SPECTROSCOPY
3.1 ABSTRACT
Circular Dichroism (CD) spectroscopy is an excellent tool for the rapid determination of
peptide secondary structures and their stabilities in the far UV region (190 – 260 nm). In this study,
the Pep42-poly(L/D-arginine) series were analyzed by CD spectroscopy to determine trends in
peptide folds in aqueous media (H2O and phosphate buffered saline, PBS) and organic solvent
(2,2,2-trifluoroethanol, TFE). The peptides were found to exhibit secondary structural features
which contained both helical and turn conformations that were contingent on sequence and solvent.
Moreover, the peptide secondary structures were found to be influenced by the Pep42 disulfide
bond. Under reduced conditions (dithiothreitol, DTT), the sequence transitioned to a random coil
in water. Interestingly, the Pep42-(D-arginine) sequences exhibited similar trends in their folded
structures. However, with noticeable inversion in peptide conformations that were likely due to
the change in stereochemistry of the poly(arginine) residues. Thermal denaturation experiments
by CD spectroscopy revealed peptide structural stabilities. Notably, increasing temperatures (25–
85 oC) produced significant changes in the CD spectra of the Pep42-poly(arginine) sequences. In
general, peptides were found to be resistant to thermal denaturation with little random coil
observed at elevated temperatures (45–85 oC). However, at these temperatures, the peptides
produced transitions from turn-to-helix conformations illustrating the resiliency and flexibility of
the Pep42-poly(arginine) secondary structures. This feature is of particular importance to the
biology of these peptides, in which structure and stability of the Pep42-poly(arginine) sequences
may play an important role in binding to the target GRP78 receptor and internalization within
cancer cells for activity (Chapter 4).
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3.2 INTRODUCTION
3.2.1 STRUCTURAL STUDIES OF PEPTIDES USING CD SPECTROSCOPY
The CD spectroscopy of peptides refers to their differential absorption of right and lefthanded circularly polarized light (Figure 3.1).1 In this technique, unpolarized light typically
emanating from a Xenon arc lamp is converted to plane-polarized radiation. Light is then split into
right and left-handed circularly polarized components by the passage through a circular polarizer
in an alternating electric field. The interaction of the circularly polarized light with chiral
chromophores (e.g. peptides) in the sample cell produces a CD signal (ellipticity) as a function of
wavelength in the UV (190 - 350 nm) region. As such, the CD spectrum provides a unique trace
that is contingent on the nature of the chromophore and the asymmetric global conformation of
the molecule.

Figure 3.1. CD spectroscopy method and sample analysis.1 Figure adapted from Ranjbar, B. et al
Chem. Biol. Drug. Des. 2009, 74, 101-120.

More specifically, CD spectroscopy allows for the rapid evaluation of peptide secondary
structures, elucidation of their thermodynamic properties and can provide important mechanistic
information on their binding properties with other ligands.2 Therefore, CD spectroscopy is a useful
characterization technique for peptides in order to gain a better understanding of their biological
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properties. Other methods can be used to elucidate peptide structures such as computational
analyses,3 mass spectrometry,4 nuclear magnetic resonance (NMR) spectroscopy,5 and X-ray
crystallography.6 CD spectrophotometry retains two advantages over these other laborious
techniques, speed and versatility.1,2 This is because CD spectroscopy provides a non-destructive
method of analyses that can facilitate high-throughput screening of multiple peptide samples in
short scanning times (min). This provides opportunity for exploring peptide structure, bio-physical
and biological properties.
Peptides are perfectly suitable to the CD study since they are chiral molecules that have
the ability to absorb electromagnetic radiation in the far (190 – 260 nm) and near (260 – 350 nm)
UV region. The interaction of the peptide backbone with light in the far UV-region produces a CD
spectrum that is contingent on the peptide secondary structure. This provides reliable information
on the different types of peptide secondary structures in terms of helices, sheets and turn
conformations (Figure 3.2, i).1,2 For example, a random coil has a broad positive n→π* electronic
absorption transition centered around 210 nm and an intense negative π→π* transition at about
190 nm. A -sheet has a negative π→π* transition in between 230 and 210 nm in addition to a
strong positive n→π* transition centered around 196 nm. Peptide turns also have characteristic
CD spectra, with a strong positive n→π* transition in between 220 and 200 nm and a negative
band at 190 nm. The CD signature for an -helix leads to a strong positive π→π* transition at 192
nm, a weaker negative one at 208 nm and a negative n→π* transition of equal intensity, albeit red
shifted at 222 nm. Thus, the CD spectrum in the far UV region (190 – 260 nm) provides a
characteristic trace for the peptide backbone geometry shown in Figure 3.2,i that is contingent on
the φ and ψ peptide dihedral angles shown in Figure 3.2,ii,7 the chirality and absorptivity of the
peptide in solution (Figure 3.2, ii).1,2
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i.

ii.

Figure 3.2. Characterization of peptide secondary structures by CD spectroscopy i. Far UV (180 – 260 nm)
CD spectra associated with peptide secondary structures: solid curve, α-helix; long dashes, anti-parallel βsheet; dots, type I β-turn; dots and short dashes, irregular structure. ii. Peptide dihedral angles (φ, ψ) of the
α-helix, β-sheet and β-turn secondary structures.1,2,7 Figure adapted from Ranjbar, B. et al Chem. Biol. Drug.
Des. 2009, 74, 101-120; Greenfield, N.J. et al Anal. Chem. 1999, 18, 236-244; Ostermeir, K. et al J. Comput.
Chem. 2014, 35, 150-158.
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Absorption of the aromatic side-chains in the near UV (260 – 350 nm) region can provide
important information on peptide tertiary structures. For example, the absorption of aromatic
amino acid side chains such as the indole group in tryptophan (280nm: 5560 L.mol-1.cm-1), the phenol
group in tyrosine (280nm: 1200 L.mol-1.cm-1), the phenyl group in phenylalanine (260nm: 195 L.mol1.

cm-1) and the imidazole functional group in histidine (211nm: 5700 L.mol-1.cm-1) can all relay

important structural information of the peptide (e.g. hydrophobic binding sites)8 or interactions
with bound ligands (e.g. π-ion interactions).9 In the near UV absorption region, disulfide bond
absorptions in between cysteine residues have been found to occur weakly at around 260 nm.
However, the intensity of this signal can be affected by the neighboring amino acid residues.10 The
changes in the CD spectra of natively folded (disulfide linked) or denatured (free thiol) peptides
provides important structural and thermodynamic information associated with the fold-to-coil
transition.1,2,10 Therefore, CD spectroscopy has gained widespread use for the determination of
peptide structures in addition to the study of other peptide properties such as thermodynamic
stability.
3.2.2 THERMAL STABILITY OF PEPTIDES USING CD SPECTROSCOPY
CD spectroscopy can also be used to monitor the thermodynamic stabilities associated with
changes in peptide secondary structures in the presence of a denaturation agent. For example,
chaotropic salts such as guanidine hydrochloride, GdnHCl, that denature polypeptides by
disrupting the non-covalent hydrogen bonds have been used to assess the thermodynamics
associated with the unfolding of a colicin E1 channel peptide with increasing [GdnHCl]. 11 The
anionic detergent, sodium dodecyl sulfate, SDS, has also been commonly used to denature
polypeptides and to provide them with a net negative charge for separation on a polyacrylamide
gel electrophoresis, PAGE.12 PAGE is a technique that separates biological molecules such as
large polypeptides based on their mass-to-charge ratio as well as conformation. The samples are
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loaded into wells at the top of the polyacrylamide gel and an electric field is applied. Since SDS
provides the polypeptide with a negative charge these polypeptide fragments migrate to the
positive electrode with smaller fragments moving faster and larger polypeptides being retained by
the gel.12 Similarly, changes in pH have drastic effects on peptide structures and activity. For
example, the unfolding of hepatic stimulator substance, HSS, a 31 kDa growth promoting factor
with an acidic isoelectric point (pI: 4.5) retained biological activity from pH: 4-10.13 Solvent
effects such as buffers with varying ion strengths and solvents have also been shown to influence
the stability of the peptide folds.1,2 For example, 2,2,2-trifluoroethanol, TFE, is most commonly
used to stabilize peptide conformations by limiting accessibility of water into the peptide thereby
lowering the dielectric constant and reinforcing hydrogen bonds between the carbonyl and amidic
NH groups.19 This has been found in the -turn geometry observed within the first extracellular
loop (residues 92-100) of the angiotensin II AT1a receptor.14 In contrast, buffers with varying ionic
strengths have been used to study the influence of electrostatic interactions on the yeast prion
peptide aggregation providing greater mechanistic insight on the thermodynamics associated with
the protein mis-folding disorder.15 Although these methods are highly insightful in studying the
energetics, stabilities and mechanisms associated with the changes in peptide conformations, these
denaturation conditions are often irreversible, making the reconstitution of the biologically active
peptide structure difficult to accomplish. Thermal denaturation is a commonly used and reversible
method for denaturing peptide secondary structures. It can provide structural information based on
temperature changes and correlate peptide folding patterns with their thermodynamic stabilities.16
Thus, thermal denaturation experiments of the Pep42-poly(arginine) series using CD spectroscopy
is perfectly suitable for determining the stabilities of the biologically active peptide folds.
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3.3 CHAPTER OBJECTIVES
The main objective of this thesis chapter involves the structure elucidation and evaluation
of the thermal stabilities of the Pep42-poly(L/D-arginine) sequences. CD spectroscopy is the
method of choice for providing quick and reliable structural data of the peptides in solution. This
study will be conducted in aqueous conditions (H2O, phosphate buffered saline, PBS) to determine
the influence of salt on peptide conformation. Moreover, the study of peptide structures will also
be determined in TFE, a commonly employed organic solvent that has been shown to stabilize
peptide secondary structures in solution.14,19 The conformational properties of the Pep42-poly(L/Darginine) sequences will be compared to the native Pep42 and poly( L/D-arginine) controls to
determine the influence of each component on peptide geometry. Moreover, the importance of the
disulfide bond in the Pep42 sequence will also be determined by the addition of a suitable reducing
reagent (e.g. DTT). These studies are important for elucidating the biologically active peptide
structure. With accurate determination of the peptide fold, thermal denaturation experiments using
CD spectroscopy will be used to delineate the stabilities of the peptide structures. This experiment
will also correlate the influence of the Pep42 disulfide bond on the stabilities of the peptide
geometries. In sum, CD spectroscopy will be used to determine the structural properties of the
Pep42-poly(L/D-arginine) sequences. With these data, peptide biological properties will be next
investigated (Chapter 4) to complete our structure-activity relationship studies.

3.4 RESULTS AND DISCUSSION
3.4.1 EFFECT OF SOLVENT ON PEPTIDE STRUCTURE
Peptides (Table 2.1, sequences 2.1-2.9, 2.16) (50 µM) were dissolved in water, phosphate buffer
and TFE to determine the influence of solvent on conformation. Interestingly, all of the peptides
exhibited folded secondary structures in the three solvent conditions. In water, Pep42 displayed a
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CD signature which was consistent with helical-type structure, with characteristic minimum bands
near 210 and 220 nm and a positive one near 190 nm (Figure 3.3).1,2,21-23 In TFE and PBS solvents,
Pep42 was found to transition from helix to turn geometry, with characteristic Cotton effects for
β-turn structures observed at around 230 nm and near 210 nm.1,2,23,24 The greater proportion of βturn structure observed for the Pep42 sequence in PBS and TFE suggests the favorable influence
of ionic interactions13 (PBS) and amphiphilic effects14,19,24 (TFE) in stabilizing the β-turn (Figure
3.3). This geometry is perhaps centered around the Pro-Gly residues and stabilized by the terminal
disulfide bond.25,26 Interestingly, in water the reduced Pep42 (free thiol) exhibits a change in
conformation from helical to random coil with increasing temperatures (Figure 3.15), highlighting
the stabilizing influence of the disulfide bond in Pep42 secondary structure.

Figure 3.3. CD spectra for Pep42 (Table 2.1, sequence 2.1, 50 µM) in water, TFE and PBS at 25 °C.

In comparison, the poly(arginine) sequence, R9 (Table 2.1, sequence 2.16, Figure 3.4)
exhibited a CD spectrum that was found to be typical of a turn geometry in water and PBS solvents,
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with a maximum at around 220 nm and a minimum band near 200 nm.1,2,23,24 The secondary
structures of poly(arginine) or arginine rich peptides have been found to be highly variable, with
strong dependence on solvent, pH effects and the lengths of the poly(arginine) sequences.27 In this
case, R9 was found to maintain a turn-type geometry in water, PBS and TFE, albeit with noticeable
shifts in in the amplitudes of the molar ellipticities at the characteristic wavelengths for turn
geometries (Figures 3.2 and 3.4).1,2,23-26

Figure 3.4. CD spectra for R9 (Table 2.1, sequence 2.16, 50 µM) in water, TFE and PBS at 25 °C.

Consequently, the Pep42-poly(arginine) sequences (Table 2.1, sequences 2.2-2.5) were found
to exhibit peptide secondary structures with varying proportions of turn or helical motifs that were
dependent on the sequence, length of the poly(arginine) and solvent conditions (Figures 3.5-3.8).
For example, the Pep42-R3 sequence (Figure 3.5) produced a CD spectrum which transitions from
helix to turn conformations, as demonstrated by the shift in amplitudes of the molar ellipticities at
around 190, 210 and 220 nm. In the case of the lengthier Pep42-R12 (Figure 3.8) the peptide
maintained a β-turn geometry with characteristic minimum bands at 230 and 200 nm and a
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maximum at 210 nm. 1,2,23-26

Interestingly, the CD spectra for the polypeptides in TFE buffer

(Figure 3.5-3.8) shows characteristic minimum bands close to 230 nm and maximum bands near
210 nm which correlates to a type I β-turn conformation.14 Moreover, the Pep42-poly(D-arginine)
series (Appendix Figures A32-A39) produced similar trends with the various solvent conditions.
The CD spectra also contained noticeable inversions in structures relative the Pep42-poly(Larginine) sequences due to the change in stereochemistry at the arginine residues. Thus, the Pep42poly(arginine) sequences (Table 2.1, sequences 2.1-2.5) exhibit secondary structures with varying
proportions of turn and helical geometries that are contingent on sequence, length of the
poly(arginine) and solvent conditions. The structural stabilities of the peptides were next assessed
to determine the resiliency of the peptide folds to thermal denaturation.

Figure 3.5. CD spectra for Pep42-R3 (Table 2.1, sequence 2.2, 50 µM) in water, TFE and PBS at 25 °C.
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Figure 3.6. CD spectra for Pep42-R6 (Table 2.1, sequence 2.3, 50 µM) in water, TFE and PBS at 25 °C.

Figure 3.7. CD spectra for Pep42-R9 (Table 2.1, sequence 2.4, 50 µM) in water, TFE and PBS at 25 °C.
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Figure 3.8. CD spectra for Pep42-R12 (Table 2.1, sequence 2.5, 50 µM) in water, TFE and PBS at 25 °C.

3.4.2. THERMAL STABILITY OF PEPTIDE STRUCTURES
The thermal stability of the peptide secondary structures observed in water was next studied by
acquiring the CD spectrum as a function of temperature (25-85 oC) in the far-UV region (190-260
nm). At room temperature (25 oC), the peptides exhibited the secondary conformations that were
observed in Figures 3.3-3.8. Elevated temperatures (35-85 oC), produced significant changes in
the peptide secondary structures (Figure 3.9.-3.15). For example, the Pep42 sequence (Table 2.1,
sequence 2.1) produced a turn-to-helix transition with increasing temperatures, causing notable
changes in the amplitudes of the molar ellipticities at 230, 210 and 190 nm (Figure 3.9).
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Figure 3.9. Temperature dependent (25 – 85 oC) CD spectra for Pep42 (Table 2.1, sequence 2.1, 50 µM).

In comparison, the poly(arginine) sequence (R9, Table 2.1, sequence 2.16) produced a
turn geometry at room temperature (Figure 3.4) which was surprisingly upheld, even at elevated
temperatures (35 – 85 oC). In spite of this stability, noticeable decreases in the amplitudes of the
molar ellipticies at the characteristic wavelengths (230, 210 and 200 nm) for the β-turn structures
were observed (Figure 3.10). The β-turn structures in arginine–rich sequences have been observed,
although with the concomitant addition of stabilizing agents such as a lipids.28

Figure 3.10. Temperature dependent (25 – 85 oC) CD spectra for R9 (Table 2.1, sequence 2.16, 50 µM).
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Within the Pep42-poly(arginine) series (Table 2.1, sequences 2.1-2.5), turn-to-helix
transitions with increasing temperatures (25-85 °C) were observed. These were characterized with
significant changes in the amplitudes of the molar ellipticities occurring at 230, 210 and 190 nm
(Figure 3.11-3.14). With exception, the Pep42-R6 sequence (Table 2.1, sequence 2.3, Figure
3.12) was found to exhibit a turn-to-coil transition, with the characteristic random coil negative
minimum at 190 nm becoming apparent at elevated temperatures (45 – 85 oC). Moreover, the
Pep42-poly(D-arginine) series (Table 2.1, sequences 2.6-2.9, Appendix Figures A33-A39)
produced similar trends during the thermal denaturation experiments. The CD spectra also
contained noticeable inversions in the structures relative the Pep42-poly(L-arginine) sequences
due to the change in stereochemistry at the arginine residues. Thus, increasing temperatures (25 85 °C) were found to trigger dynamic changes in peptide conformations without denaturing peptide
structure to random coil. This result is not entirely surprising considering under non-reducing
conditions disulfide bonds have been shown to maintain stable peptide secondary structures.26
Moreover, the decrease in the molar ellipticities at the characteristic wavelengths describing
peptide structure suggests that the non-covalent interactions, (hydrogen bonding) are disrupted at
elevated temperatures compromising the peptide fold. This data also suggests that the observed
peptide secondary structures at elevated temperatures (45 – 85 oC) were stabilized by the Pep42
disulfide bond. In order to validate the influence of the disulfide bond on peptide structure and
stability, the Pep42 sequence was reduced (DTT) to the free thiol. In this case, reduced Pep42 was
found to adopt a helix type structure at ambient temperature and transitioned to a random coil at
elevated temperatures (35-85 oC) (Figure 3.15). Therefore, peptides were found to readily
interconvert between helix and turn geometries while generally resisting peptide secondary
structure thermal denaturation in their cyclized forms.
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Figure 3.11. Temperature dependent (25 – 85 oC) CD spectra for Pep42-R3 (Table 2.1, sequence 2.2, 50
µM).

Figure 3.12. Temperature dependent (25 – 85 oC) CD spectra for Pep42-R6 (Table 2.1, sequence 2.3, 50
µM).
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Figure 3.13. Temperature dependent (25 – 85 oC) CD spectra for Pep42-R9 (Table 2.1, sequence 2.4, 50
µM).
.

Figure 3.14. Temperature dependent (25 – 85 oC) CD spectra for Pep42-R12 (Table 2.1, sequence 2.5, 50
µM).
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Figure 3.15. Temperature dependent (25 – 85 oC) CD spectra for linear Pep42 (Table 2.1, sequence 2.1,
50 µM).

3.5 CONCLUSIONS
The structures and thermal stabilities of the Pep42-poly(arginine) sequences (Table 2.1,
sequences 2.1 – 2.15) were evaluated in this study. Specifically, the Pep42 sequence was found to
display stable folded geometries in aqueous (H2O, PBS) and organic solvent (TFE) which
transitioned from helix and turn conformations (Figure 3.3). In comparison, the poly(arginine)
sequence, R9, displayed a CD spectrum that was consistent with that of a stable β-turn
conformation (Figure 3.4). Interestingly, turn-to-helix interconversions were observed for the
Pep42 sequence while the poly(arginine) sequence maintained a stable turn geometry at elevated
temperatures (45 – 85 oC). Consequently, the Pep42-poly(arginine) sequences demonstrated CD
spectra that contained varying proportions of helix and turn conformations in water and PBS
solvents that were dependent on the lengths of the poly(arginine) sequences (Figure 3.5-3.8).
Similar trends on the thermal stabilities of the peptide structures were observed (Figure 3.11-3.14),
with notable turn-to-helix transitions observed in most cases, while resisting peptide unfolding at
the elevated temperatures (45 – 85 oC). The Pep42 disulfide bond was found to play a pivotal role
62

in maintaining stable peptide secondary structures. Therefore, the Pep42-poly(arginine) peptides
(Table 2.1, sequences 2.1-2.5) were found to exhibit versatile folds, in which helix and turn-type
secondary structures were found to be contingent on solvent, sequence and length of the
poly(arginine) residues. These structural properties may translate into important peptide biological
activities that are geared towards the development of a targeted gene therapy approach in cancer
cells (Chapter 4).
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3.7 EXPERIMENTAL SECTION
3.7.1 MATERIALS
Purified water, 2,2,2-trifluoroethanol (TFE), Calbiochem (San Diego, CA), ammonium
bicarbonate, dithiothreitol (DTT), acetic acid, sodium chloride, potassium chloride, disodium
phosphate, monopotassium phosphate were all purchased from Aldrich (Milwaukee, WI) and used
without further purification.

3.7.2 DISULFIDE REDUCTION
Reduction was performed by dissolving purified, cyclic Pep42 (1.0 mg, 1.0 mol) in ammonium
bicarbonate pH 8.4 (1.0 mL, 0.1 M). Dithiothreitol (DTT) (1.0 mL, 1.0 M) solution was added and
the mixture was reacted under an atmosphere of nitrogen at room temperature (22 oC) for 6 h. The
reaction was quenched with acetic acid (5.72 µL, 0.1 M) and lyophilized to dryness overnight prior
to LCMS analysis.

3.7.3 INSTRUMENTAL PARAMETERS FOR CD SPECTROSCOPY
The CD spectra of the peptide samples were collected in high-transparency rectangular
quartz cuvettes (Fisher Scientific, Pittsburgh, PA) with a path length of 1.0 cm. These were placed
in calibrated, temperature regulated cell holders in an Aviv 62A DS CD spectrophotometer
(Lakefield, NJ). Baselines for all the cuvettes in the presence of buffer or solvent were collected
before each sample scan. Prior to sample analyses, the instrumental parameters relating to
bandwidth, time constant, scan rate and the number of scans were optimized. 2 The bandwidth
measures the precision at which the monochromator selects light at a specific wavelength for
sample analysis. For peptide analyses, the bandwidth was optimized at 1.0 nm. The time constant
or the scan rate measures the time in which the CD data is averaged. Typically, increasing the scan
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rate provides greater data acquisition which improves the resolution of the CD spectra. The scan
rate for the CD spectra collected in this study was set at 0.5 min. The number of scans is an essential
component for confirming sample reproducibility. An average scan is collected in 5 – 10 min and
the data acquisition is repeated (N = 3) to confirm reproducibility of the results. Moreover,
increasing the number of scans will also improve the signal to noise (S/N) ratio resulting in spectra
with greater resolution and sensitivity.
3.7.4 PREPARATION OF BUFFERS AND SOLVENTS FOR CD SPECTROSCOPY
The buffers and solvents used for sample preparation must not contain any chromophores
within the selected wavelength region for CD analyses. In order to confirm their transparency, the
CD spectrum of the buffer or solvent alone (no sample) was collected and referenced as baseline.
In this study, three solvent conditions were selected and applied to evaluate the effect of solvent
on peptide structure and stability. Distilled water (pH 7.0), phosphate buffered saline (PBS)
consisting of NaCl (8.0 g), KCl (0.2 g), Na2HPO4 (1.4 g), KH2PO4 (0.2 g) dissolved in distilled
water (1.0 L) and adjusted to pH 7.4, were selected to explore the influence of pH and ionic
strength on peptide structure and stability.1,2,13 The solvent 2,2,2-trifluoroethanol (TFE) was also
selected to explore the influence of an organic solvent known to stabilize peptide secondary
structures14,19 on the conformations of the Pep42-poly(arginine) sequences. Prior to sample
preparation, TFE was degassed by passage through a 0.2 µm filter which also removed highly
scattering particles that can interfere with the sample analysis.17 If the total absorbance exceeds
approximately one unit, the spectral noise will become excessive and approach an automatic cutoff
which may abort the acquistion.18 It has been shown that overlapping signals arise from absorption
characteristics of buffers and other reagents in the far UV range.17-19 For example, TFE has a UV
cut-off at 190 nm, while the PBS buffer has a low absorbance above 190 nm and does not interfere
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with peptide absorptions in between 214 and 260 nm which makes it a suitable solvent for the CD
application of peptides in a desired pH range (6 - 9.5).20
3.7.5 PREPARATION OF PEPTIDES FOR CD SPECTROSCOPY
The synthesized peptides in this study (Chapter 2) were isolated in purities >95% by RPHPLC and characterized by LC/MS making them suitable for CD structural analyses. The
concentration of the peptides in water (1.0 mL) was determined by UV-Vis absorption
measurements at 280 nm followed by quantitative analyses using the Beer-Lambert equation
(equation 3.1). The selected wavelength (280 nm) was based on the molar extinction coefficient
for tyrosine (: 1280 M-1cm-1) which allowed for the precise and reproducible determination of the
absolute absorption values (A280) for the Pep42-poly(L/D-arginine) sequences. The stoichiometric
measurements were then calculated from the Beer-Lambert law (equation 3.1) which correlates
the absorption of the tyrosine residue in the peptide sample at 280 nm (A280nm) with its
concentration (c, mol/L), the molar extinction coefficient of the tyrosine residue in the peptide
sequence (, Lmol-1cm-1) and the path length of the cuvette (l, cm).

A280nm =  c l

(3.1)

Peptide samples were prepared at 50 µM in distilled water (pH 7.0), PBS buffer (pH 7.4)
and TFE solvent. The samples were then degassed by passage through a 0.2 µm filter which
removed highly scattering particles that may interfere with the absorption measurements of the
peptide sample in solution. Exactly 1.0 mL of each of the three solvents were dispended into hightransparency rectangular quartz cuvettes (Sigma-Aldrich, Milwaukee, WI) with a path length of
1.0 cm and the baseline at 280 nm was collected and referenced prior to the sample scans.
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3.7.6 DATA ACQUISITION
The cuvettes containing the blank or peptides were placed in the sample cell holder and
flushed with nitrogen for 20 minutes while the lamp was cooled with a temperature-regulated
circulating water bath. At a temperature of 25 °C the CD data was collected in between 190 – 260
nm. The CD spectra collected the signal as a change in sample molar ellipticity (dynode voltage)
with changes in wavelengths. Samples were blank corrected, smoothed and the data converted to
molar ellipticity values from the equation [θ] = θ /cl, where θ is the relative ellipticity (mdeg), c is
the molar concentration of the peptides (M) and l is the path length of the cell (10 mm). The data
was imported into Microsoft Excel and the CD spectra were plotted in terms of molar ellipticity,
[θ], vs wavelength (nm). Temperature dependent studies were determined by equilibrating peptide
samples (50 µM) in autoclaved distilled water (pH 7.0) at a given temperature (25-85 oC) for 5.0
min under N2 and collecting the spectrum as previously described.
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CHAPTER 4: BIOLOGICAL ACTIVITY OF CANCER-TARGETING
PEPTIDES IN HEPG2 HEPATOBLASTOMA CELLS
4.1 ABSTRACT
The specific delivery of GRP78-silencing siRNA into HepG2 cancer cells is described in
this study. The use of GRP78-targeting Pep42 in combination with various lengths of
poly(arginine) sequences (3-12) were initially evaluated for their ability to bind to GRP78 and
internalize within HepG2 cells by flow cytometry. These cancer-targeting peptides retained the
ability to bind to GRP78, while demonstrating cell translocation activity that was highly contingent
on the lengths of the poly(arginine) sequences. Moreover, peptides were not found to trigger
HepG2 cell death. In combination with GRP78-silencing linear, branch and hyperbranch siRNAs,
the complexes formed between the cancer-targeting peptides and the siRNAs (CTP:siRNA) were
characterized by PAGE, CD spectroscopy, thermal denaturation, TEM and DLS. These
experiments confirmed the formation of higher-ordered complexes between the CTP:siRNAs that
were found to be stable towards thermal denaturation (25-85 oC) while resisting degradation in
biological media (FBS in DMEM). Transfection of a linear GRP78 silencing siRNA in complex
with the CTP-R9 (Table 2.1, sequence 2.4) sequence within HepG2 liver cancer cells led to
significant GRP78 silencing (50-60%) and modest cell death (5-15%) which paralleled the results
obtained from the benchmark Lipofectamine transfections. These results suggests that the CTPR9 sequence and related CTPs may function as useful GRP78-targeting transfection agents in a
wide range of cancer cell types that display the cell surface GRP78 receptor. This discovery is an
important contribution towards the development of an effective cancer-targeted gene therapy
approach.
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4.2 INTRODUCTION
4.2.1. APPLICATION OF PEP42 TO GRP78 TARGETING IN CANCER
Although many biological molecules have emerged as useful cancer therapeutics, three
major drawbacks continue to limit their translation to clinical use.1 Firstly, good cellular uptake
typically requires the administration of high sample doses in order to obtain the desired therapeutic
effects. Secondly, the efficient passage across the plasma membrane remains a major hurdle for
the delivery of highly polar or charged biologicals. And thirdly, their lack of cell or tissue
selectivity limits the therapeutic index while causing widespread toxicities. In order to mitigate
these issues, cancer-targeting peptides have been explored as specific drug delivery agents. They
lead to potent anti-cancer effects and without the concomitant toxicities that are associated with
non-selective forms of therapy.2
Recent studies have demonstrated that the chaperone protein GRP783 is over-expressed
and cell surface localized on tumors, contributing to tumor growth, invasion, metastatic spread and
resistance to anti-cancer drugs.4 Therefore, GRP78 has been classified as a valid biological marker
for the development of targeted forms of cancer therapy. In the selection of high affinity and
specific ligands for GRP78, binding studies have revealed that the substrate binding domain of the
GRP78 receptor contains a groove with an affinity for neutral and hydrophobic amino acid
residues.18 This has led to the discovery of a new peptide ligand with an affinity and selectivity for
the GRP78 receptor localized on the cell surface of cancer cells but not on healthy tissues.5
Phage display bio-panning experiments6 enabled the selection of a cyclic peptide ligand,
namely Pep42, H2N-CTVALPGGYVRVC-CONH2, 2.1, which was found to bind to the GRP78
receptor (Figure 4.1).5a Pep42 possessed the ability to discriminate between the homologous Heat
Shock Protein 70 (HSP70) and ubiquitous Bovine Serum Albumin (BSA) underscoring its

71

selectivity for the GRP78 receptor.5b Thus, the Pep42-phage bound specifically to immobilized
GRP78 while no binding was observed for the other scrambled peptide control (Figure 4.1).5b

Figure 4.1. Pep42-displaying phages bind specifically to GRP78. GRP78, HSP70, and BSA were coated
on microliter wells at 10 µg/mL and incubated with either Pep42-phage or the control phage that possessed
a scrambled peptide sequence. Phage input was 109 cfu per well. Results were expressed as mean ± standard
error of the mean (SEM) of triplicate wells.5b Figure adapted from Liu, Y. et al Mol. Pharm. 2007, 4, 435447.

The selection of Pep42 as a GRP78 binding ligand prompted a series of binding
experiments with a broad range of human cell types, ranging from tumors such as melanoma
(Me6652/4), osteosarcoma (SJSA-1), hepatoblastoma (HepG2), lung adenocarcinoma (A549) and
normal human lung or dermal fibroblast (CCD-11Lu or HDFa, respectively) cell lines.5b Flow
cytometry revealed that the FITC-labeled Pep42 (red curve) bound to the cell surface of tumor
cells but not the normal controls (Figure 4.2, A). Conversely, the scrambled FITC-labeled peptide
control (green curve) did not demonstrate any significant binding affinity to the cell types (Figure
4.2, A). An anti-GRP78 polyclonal antibody was then used to determine binding specificity by
blocking cell surface GRP78 on the HepG2 cells prior to FITC-labeled Pep42 treatment. In this
case, a drastic decrease in the fluorescence signal was observed relative to the unblocked control
(Figure 4.2, C). To further validate the Pep42:GRP78 binding interaction, a photoaffinity labeling
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experiment was conducted to covalently bind Pep42 to the GRP78 receptor prior to western
blotting (Figure 4.2, B). These results confirmed the Pep42:GRP78 binding interaction on the
tumor cells (HepG2 and Me6652/4) but not on the normal human cells (HdFa). Furthermore,
knockdown of GRP78 with siRNA treatment (Figure 4.2, D) abolished Pep42 binding to the
GRP78 receptor, lending additional support for the GRP78 binding specificity of the Pep42 ligand
on the surface of solid tumors.5b

Figure 4.2. Pep42:GRP78 binding on the surface of tumor cells. A) Cells incubated with either 50 nM
FITC- Pep42 (red curve) or FITC- scrambled peptide (green curve) for 25 min at 4 °C. The black curves
correspond to cells incubated in the absence of any peptide. B) Pep42 binding to tumor cells using
photoaffinity labeling. C) Inhibition of Pep42 binding to HepG2 cells by blocking with anti-GRP78
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antibody followed by Pep42 or scrambled peptide treatment. **Difference of cells treated with Pep42 only,
Student’s t test, p < 0.01. D) Effect of GRP78 silencing on Pep42 binding to Me6652/4 cells. 5b Figure
adapted from Liu, Y. et al Mol. Pharm. 2007, 4, 435-447.

Confocal laser scanning fluorescence microscopy was used to provide additional evidence
for the Pep42:GRP78 cell surface binding and to explore translocation activity.5 Pep42-quantum
dots (Pep42-QD) were applied for tracking cellular localization in A549 osteocarcinoma cells.5b
In combination with transferrin and cholera toxin subunit B, Pep42 was found to bind to GRP78
harboring A549 cells and to accumulate in the endoplasmic reticulum with these known markers
of endocytosis.7,8 In order to elucidate the mechanism of Pep42 intracellular transport, several
inhibitors of endocytosis were examined, including a known inhibitor of clathrin mediated
endocytosis, chlorpromazine.9 In its presence, Pep42 and transferrin did not internalize within
A549 osteocarcinoma cells (Figure 4.3). Considering transferrin has been shown to internalize
within cells by clathrin mediated endocytosis7, Pep42 was speculated to internalize within cells in
a similar mechanism.5b
Considering the GRP78 targeting and specific internalization within cancer cells but not
in normal cell types, Pep42 was next evaluated as a targeting vector for the selective delivery of
anti-cancer drugs in tumors.5 Pep42 has been effectively conjugated with potent
chemotherapeutics (Taxol and Doxorubicin), photosensitizers (hematoporphyrin) and the
apoptotic D-(KLAKLAK)2 sequence for eradicating tumors in-vitro and in mouse bearing tumor
models.5 Therefore, the specific Pep42:GRP78 binding interaction may form the basis for the
development of new and improved drug delivery methods in cancer treatment.
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Figure 4.3. Pep42-QD internalization within A549 osteocarcinoma cells. Comparison of labeled Pep42QD-525 vs. AF-594 transferrin with and without incubation of known inhibitors of endocytosis (25 µM
nystatin, 30 µM chlorpromazine and 5 mM methyl β-cyclodextrin). Figure adapted from Liu, Y. et al Mol.
Pharm. 2007, 4, 435-447

4.2.2. POLY(ARGININE) CELL PENETRATING PEPTIDES AS siRNA DELIVERY
AGENTS
Small interfering RNA (siRNA) has shown great potential in the RNA interference (RNAi)
method for gene therapy by silencing malignant mRNA expression that is associated with a wide
range of genetic disorders, especially in cancer.10 In spite of their potential utility, siRNAs are
plagued by poor pharmacokinetic properties which includes, poor cell permeability and stability,
which limits their therapeutic efficacy.11 Therefore, a suitable carrier (i.e. transfection reagent) is
necessary to facilitate the intracellular delivery of siRNA for the RNAi application. The siRNA
carriers are based on viral12, synthetic polymers13 and biomacromolecule14 vectors that have the
ability to condense and deliver siRNA across the amphiphilic plasma membrane. Albeit these
transfection methods have shown promising preliminary results in-vitro and in-vivo, they do suffer
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from inherent limitations which restricts their widespread utility. For example, viral vectors and
synthetic polymers are afflicted by aberrant toxicities and poor specificities. Meanwhile
biomacromolecules tend to degrade rapidly in biological media providing short therapeutic
indices.11 In an effort to address these limitations, poly(arginine) peptides have been employed as
efficient siRNA condensing and transfection reagents in cancer cells and in subcutaneous tumor
bearing mice models. For example, the arginine peptide-mediated delivery of HER-2 siRNA
induced inhibition of tumor growth in vivo (Figure 4.4).15 Moreover, poly(D-arginine) peptides
have been shown to confer greater metabolic stability due to the un-natural D-Arg residues, thereby
improving pharmacokinetic properties. However, their lack of tissue specificity results in
widespread dispersion of siRNAs in almost all cell types, resulting in detrimental ‘off-target’ gene
silencing which compromises the treatment method.19 In order to mitigate these side-effects,
cancer-targeting peptides have been coupled to poly(arginine) sequences to facilitate the selective
internalization of siRNA into tumors for RNAi activity. This strategy has been applied for the
transvascular delivery of siRNA into the central nervous system with the use of an acetylcholine
receptor (AchR) targeting peptide (RVG) that was coupled to a nona-arginine (R9) sequence.16
Thus, the combination a cancer-targeting peptide with a poly(arginine) sequence forms the basis
of a cancer-targeting gene therapy approach.
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Figure 4.4. Arginine+siRNA inhibition of tumor growth in nude mice. SKOV-3 cancer cells (5×106
cells/mouse) were transplanted in the mice. Once the tumors reached approximately 100 mm3, the mice
were treated with arginine/HER-2-specific siRNA, arginine/HER-2-mismatched siRNA, or naked siRNA.
As control, 5% glucose solution (placebo) was injected. Data=mean, n=6. S.D. of the data points is not
shown for clarity.16 Figure adapted from Kim, S.W. et al J. Control. Rel. 2010, 143, 335-343.

4.3 CHAPTER OBJECTIVES
The main objective of this thesis chapter involves the biological study of the Pep42poly(arginine) series (Table 2.1, sequences 2.1-2.5). In collaboration with Drs. Allan D. Blake,
Constantine Bitsaktsis (Department of Biological Sciences, Seton Hall University) and students,
Brittany Blackman MSc, Christopher Parronchi (BSc student), Megan Kelly (PhD student) and
Mariana Phillips (PhD student) peptide biology in HepG2 cells will be studied. The peptideGRP78 binding interaction will be evaluated by flow cytometry. FITC-labeled peptides will be
added to the GRP78 harboring HepG2 cells in order to determine binding affinity by fluorescence
measurements. GRP78 binding selectivity will also be determined by flow cytometry. In this case,
an unlabeled anti-GRP78 polyclonal antibody will be used to block GRP78 prior to the

77

administration of FITC-labeled peptides. A decrease in fluorescence signaling relative to the
control experiment (FITC-peptide+HepG2 cells) will indicate peptide binding specificity.
Furthermore, a Trypan blue cell death assay will be used to assess the cytotoxicities of the peptides
prior to siRNA complex and transfection studies. The combination of Pep42-poly(arginine)
sequences, CTP (Table 2.1, sequences 2.2-2.5) with linear, branch and hyperbranch GRP78silencing siRNAs17 is expected to produce stable higher-ordered complexes that will be
characterized by PAGE, thermal denaturation, TEM and DLS. Dr. Uri Samuni (Department of
Chemistry, Queen’s College CUNY) and Reeta Yadav (PhD student) will assist with the TEM
images and DLS measurements. With completed characterization of the CTP:siRNA complexes,
transfection experiments will be conducted in HepG2 cells to determine the extent of GRP78
silencing and cancer cell death. These experiments will provide the necessary foundation for the
development of our cancer-targeting gene therapy approach (Figure 4.5).
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Figure 4.5. Proposed cancer-targeting gene therapy approach.
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4.4 RESULTS AND DISCUSSION
4.4.1. SELECTION OF HEPG2 HEPATOBLASTOMA CELLS
Hepatoblastoma (HB) is an embryonal form of liver cancer that is found in childhood and
in the early stages of adolescence.19 HepG2 hepatoblastomas have been isolated and cultured for
the pre-clinical study of pediatric liver diseases.20 The HepG2 cell line originated in 1979 by
Barbara Knowles and colleagues, ‘derived from the liver tissue of a 15 year old white male with a
well differentiated hepatocellular carcinoma’.20,21 It has also been shown that cell surface GRP78
is associated with tumor invasion in HepG2 cells making it a clinically relevant model for
validating our GRP78-targeting strategy.22
4.4.2. GRP78 BINDING AND SELECTIVITY OF FITC-PEP42-POLY(ARGININE)
SEQUENCES IN HEPG2 HEPATOBLASTOMA CELLS
The ability for the peptides to bind to HepG2 cells’ GRP78 and potentially exhibit cell
permeability was initially assessed by flow cytometry in collaboration with the Drs. Blake and
Bitsaktsis groups (Figure 4.6.). The internal fluorescence of the HepG2 cells was recorded and
normalized according to the FITC signals observed for the peptides and corresponding GRP78
antibody (Figure 4.6.A). The results showed that the peptide blocker partially (~50%) inhibited
the binding of the FITC-Ab on the cell surface of the HepG2 cells. Comparatively, FITC-labeled
Pep42 (100 nM) exhibited similar signaling activity with and without the peptide blocker,
supporting the Pep42-GRP78 binding and specificity on HepG2 cells (Figure 4.6.D and E).5a,b In
contrast, FITC-labeled poly(arginine), (FITC-R9, 100 nM), displayed similar fluorescent signaling
with and without the peptide blocker (10 mg/mL), illustrating non-specific HepG2 cell binding
(Figure 4.6.F and G). Moreover, the FITC-signaling activity for this peptide was found to be 5fold greater than the FITC-Ab and the FITC-Pep42, suggesting internalization may contribute to
the enhanced fluorescent signaling activity. Interestingly, the results obtained from the FITC80

labeled poly(arginine) derived Pep42 sequences (Appendix 22A-29A) were found to support this
assumption, with significant increases in fluorescent signaling on the HepG2 cells (12 – 46%) with
increasing lengths on the poly(arginine) sequences (3 – 12).

Figure 4.6. Flow cytometry data on HepG2 cells. FITC signaling collected at 521 nm on HepG2 cells (50,
000 cells/mL) alone, HepG2 cells in the presence of Alexa Fluor 488-labeled N20-anti-GRP78 primary
antibody (100 nM), FITC-labeled Pep42 (100 nM), FITC-labeled Pep42-R9 (100 nM), FITC labeled R9
without (a-e) and with (f-i) N-20 GRP78 peptide blocker (10 mg/mL). Data acquired in collaboration with
Drs. Blake and Bitsaktsis research groups.
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To support these results, laser scanning confocal microscopy was used to capture images
of the HepG2 cells incubated with the FITC-labeled peptides (Figure 4.7).

Figure 4.7. Laser scanning confocal microscopy of HepG2 cells without (a) and with (b) N-20 GRP78
blocking peptide (2.0 µg/mL). HepG2 cells (50, 000 cells/mL) were incubated with FITC-Pep42-R9 (2.0
µg/mL) and counterstained with DAPI (0.5 µg/mL in PBS). The FITC signal from the peptides is visualized
as green whereas DAPI stains the cells’ nuclei blue. Data acquired in collaboration with the Drs. Blake and
Bitsaktsis research groups.

The FITC signaling in green was detected with the labeled Pep42-R9 sequence (2.0 µg/mL)
and found to be closely associated with the blue DAPI (Ex/Em 345/455) (0.5 µg/mL in PBS)
stained HepG2 cells’ nuclei, suggesting cell internalization (Appendix Figure 22A). There was a
reduction in the FITC signal observed when the FITC-labeled Pep42-R9 sequence was coadministered with the N-20 GRP78 blocking peptide, providing additional evidence for the CTPGRP78 binding selectivity and its correlation to cell translocation activity.5a,b In comparison,
reduced FITC signaling was observed on the HepG2 cells with the Pep42 sequence in the absence
of poly(arginine) (Appendix Figures 22A-29A). Comparable FITC signaling was observed with
and without peptide blocker for the control R9 sequence (Appendix Figures 22A-22A). These
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results correlated to the data obtained from the flow cytometry (Figures 4.6.D-G) and support the
ability for the Pep42-poly(arginine) sequences to bind to GRP78 and internalize within the HepG2
cells.

4.4.3. CELL VIABILITY OF POLY(ARGININE) DERIVED CANCER-TARGETING
PEPTIDES IN HEPG2 CANCER CELLS
The cytotoxicities of the Pep42-poly(arginine) derived cancer-targeting peptides was
assessed by comparing the number of viable HepG2 cells following incubation with peptides
(Table 2.1, sequences 2.1-2.5) over a 48 h period. Using a Trypan blue cell exclusion assay which
stains dead cells blue,23 low levels (5-10%) of cell death were observed for the peptides (Table
2.1, sequences 2.1-2.5) at 0.15 mM (Figure 4.8.A). In a dose response assay, the Pep42-R9 (Table
2.1, sequence 2.4) sequence was found to exhibit 5-10% cancer cell death at 0-1.5 mM indicating
that the peptide is an ideal candidate for drug delivery with low cytotoxicity levels (Figure 4.8.B).

Figure 4.8. HepG2 cancer cell viability following 48 h transfection with A) Pep42 (2.1), Pep42-R3 (2.2),
Pep42-R6 (2.3), Pep42-R9 (2.4) and Pep42-R12 (2.5) with a concentration of 0.15 mM and B) Pep42-R9 (2.4)
with varying concentrations (0-1.5 mM). The resulting data was collected in replicate (n ≥ 3) and analyzed
with GraphPad Prism 5.9. Statistical significance was determined by ANOVA (p < 0.05). Data acquired in
collaboration with Dr. Blake’s research group.

4.4.4. FORMATION OF CTP:siRNA COMPLEXES
To evaluate the formation of CTP-R9:siRNA complex, a gel shift assay was employed to
determine the optimal stoichiometric ratios of CTP and siRNA for complex formation. In this
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experiment, complex formation is stimulated by the electrostatic interactions in between the
polycationic CTP-R9 sequence (Table 2.1, sequence 2.4) and negatively charged siRNA. The
CTP:siRNA complex will have a slower electrophoretic mobility on a native (no urea) PAGE
relative to the unbound siRNA. This is partially related to the masking of the negatively charged
oligonucleotide, which tends to freely migrate towards the cathode of the PAGE (located at the
bottom of the gel). Specifically, a single-stranded siRNA (1.0 µmol) was mixed with the CTP-R9
(0.5-2.5 µmol) in various N:P ratios (1-50) in an annealing 30% sucrose (Tris-Acetate-EDTA)
TAE buffer (pH 8.3), incubated for 30 min at 37 oC and loaded on a native PAGE. Following
electrophoresis, the resolved samples were detected with Stains All™ dye (Aldrich) which forms
a dark blue complex with the siRNA.24 Expectedly, a decrease in the electrophoretic migration of
the siRNA with increasing quantities (0.5-2.5 µmol) of the CTP-R9 was detected (Figure 4.9).
Moreover, a decrease in the intensity of the siRNA band with increasing CTP-R9 quantities (0.52.5 µmol) was also observed, further supporting the complex formed in between the CTP:siRNA.

Figure 4.9. Native PAGE gel shift assay. Linear single strand siRNA (1.0 μmol) and increasing (1-50:1)
stoichiometric ratios of CTP-R9 (1.0 – 50 μmol).
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4.4.5. CHARACTERIZATION OF THE CTP-R9:siRNA COMPLEXES
The sizes, shapes and stabilities of the CTP:siRNA complexes were next evaluated.
Dynamic Light Scattering (DLS) measurements were initially performed on a 90 plus particle size
analyzer (Brookhaven Instruments Corporation) employing a 90o scattering angle and a 35 mW
incident laser (658 nm). CTP-R9:siRNA (13 µM, 50:1 CTP:siRNA) samples were prepared in
phosphate buffer (140 mM KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4 adjusted to pH 7) and sonicated
for 30 minutes before taking measurements. The reported effective diameters (nm) were calculated
as the average of 5 runs with the corresponding standard deviation for each sample (Table 4.1.).
The effective diameters of the complexes formed between CTP:siRNA indicated a bimodal
distribution of particles (two particle size populations). The larger particle sizes observed (1400
nm) held a >2-fold increase relative to the unbound siRNA (600 nm) or CTP-R9 (40 nm). This
data unequivocally supports the formation of the Pep42-R9:siRNA complex. DLS measurements
for the remaining CTP:siRNA complexes can be found in the Appendix Figure A65.

Sample

Effective Diameter (nm)

CTP-R9

40 ± 4

siRNA

4±1
110 ± 18
600 ± 95

CTP-R9:siRNA

210 ± 14
1400 ± 78

Table 4.1. Samples (0.05-0.15 μM) were prepared in pre-filtered (0.2 μm filter) pH 7.0 phosphate buffer
(140 mM KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4) and sonicated for 30 minutes before taking
measurements. The reported diameter is the average of 5 runs for each sample reported with the standard
deviations about the mean. Data acquired in collaboration with Dr. Uri Samuni (Queen’s College CUNY).
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Transmission electron microscopy (TEM) was next employed to obtain images of the
CTP:siRNA complexes. The collected TEM images demonstrate a variety of sizes and shapes for
the CTPs, siRNAs and their complexes (Figure 4.10). For example, the CTP-R9 (Figure 4.10, A)
displays uniformly shaped spherical structures that were well dispersed throughout the optical
grids. The peptide was much smaller (30 nm) in size compared to the siRNA alone (1500 nm) and
the siRNA:CTP complex (400 nm) (Figure 4.10, B and C). The siRNA sample displayed
aggregates of various sizes and shapes (Figure 4.10 B). Whereas, the CTP-R9:siRNA complex
induced the formation of larger sized (1000 nm) spherically shaped aggregates that were in
agreement with the effective diameters observed from the DLS measurements (Table 4.1).
Moreover, similar trends were also observed for the remaining CTP:siRNA complexes (Appendix
Figures A23-A29), underscoring the efficiency of the Pep42-R9 sequence in condensing siRNAs
of varying lengths, sequences and morphologies.

Figure 4.10. TEM images of A) CTP-R9, B) siRNA and C) CTP-R9:siRNA complex. Samples (0.13 μM)
were mixed with 1.0% uranyl acetate in ethanol (1:1 v/v), sonicated for 10 minutes, and added to a carbon
film coated copper grid, 300 mesh (electron microscopy sciences, Hatfield, PA) and dried overnight prior
to viewing under the transmission electron microscope (JEOL, model JEM-1200 EX). Images were taken
with a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc.) using the software Maxim
DL5 (Diffraction Limited, Ottawa, Canada). Data acquired in collaboration with Dr. Samuni (Queen’s
College CUNY).
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The influence of the CTP-R9:siRNA complex on peptide and siRNA secondary structure
was next evaluated by CD spectroscopy (Figure 4.11). In its free state, siRNA adopts the canonical
A-type RNA helix, which has a characteristic CD signature, with a minimum peak at around 240
nm and a broad maximum in between 255-290 nm.25 The CTP-R9 displayed a secondary structure
in PBS that was contingent on a turn conformation (Figure 3.7) characterized by a minimum band
at around 210 nm and maximum molar ellipticities centered around 220 and 190 nm.26 In
comparison, the CTP:siRNA complexes produced profound shifts in the CD spectra, with
noticeable changes in the molar ellipticities occurring at the characteristic wavelengths of their
respective secondary structures (Figure 4.11). These results also suggest the formation of higher–
ordered structures between the CTP:siRNA complexes. Similar trends were observed for the
remaining CTP:siRNA complexes (Appendix Figures A43-52).

Figure 4.11. CD spectra of CTP-R9:siRNA complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.

The thermal stabilities of the CTP-R9:siRNA complexes were next assessed by thermal
denaturation experiments at 260 nm using temperature-regulated UV-Vis spectroscopy. The
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double-stranded siRNA was found to exhibit a helix-to-coil transition25 with increasing
temperatures (5-90 oC) that produced a thermal denaturation temperature (Tm: 72 oC). Titration of
CTP-R9 (0.26 – 13 μmol) to the siRNA (0.26 μmol) produced significant changes in the thermal
denaturation curves (Figure 4.12). These changes were associated with a sharp decrease in
hyperchromicities (30% to ≤10%) which abolished the helix-to-coil transition25 in the siRNA
thermal denaturation. Presumably, at optimal CTP:siRNA (15 μM, 50:1 mol/mol) concentrations
the siRNA no longer forms a double-stranded RNA hybrid. Similar trends were observed in the
thermal denaturation curves of the remaining CTP:siRNA complexes (Appendix Figure A23).

Figure 4.12. Thermal denaturation studies of the CTP:siRNA complex. Samples were prepared
by mixing CTP:siRNA (15 μM, 1-50:1 mol/mol) in phosphate buffer (140 mM KCl, 1.0 mM
MgCl2, 5.0 mM NaHPO4) and placing on a heat block incubator set at 37 oC for 1 hour. Samples
were cooled to room temperature and placed in the fridge overnight prior to thermal denaturation
studies. Samples were then placed in a temperature regulated (5 oC) cell holder and heated (5 – 95
o

C) for sample absorption measurements at 260 nm.
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4.4.6. BIOLOGICAL ACTIVITY OF CTP:siRNA COMPLEXES IN HEPG2 CELLS
The native siRNA sequences are typically prone to nuclease digestion in biological media,
limiting their therapeutic potential.27 Thus, the ability for the CTP:siRNA complexes to maintain
metabolic stability is an important pre-requisite for effective and long-lasting RNAi activity. To
determine the serum stability of these samples, the CTP-R9:siRNA complex and siRNA alone
were subjected to a 10% fetal bovine serum (FBS) in Dulbecco’s Modified Eagle Medium
(DMEM) treatment. Aliquots were quenched at timed intervals and run on a denaturing (urea)
PAGE to resolve the samples. Stains-All™ (Aldrich) staining generated the desired siRNA bands
with and without the CTP-R9 (Figure 4.13). In this assay, the CTP:siRNA complexes retained
their integrity for up to 8 hours, (Figure 4.13, B) while the siRNA control produced degradation
products that were visible as lower migrating bands even after a 5 minute FBS treatment (Figure
4.13, A). Thus, the CTP-R9 was found to confer significant nuclease resistance to the siRNA,
while the free-form siRNA was degraded within 4 hours in 10% FBS/DMEM.

Figure 4.13. 18% denaturing (urea) PAGE of A) siRNA (20 μM) and B) CTP:siRNA (20 μM) in 10% FBS
in DMEM. Samples were incubated (0.15 mL, 10% FBS/DMEM) at 37 oC and at measured time points,
aliquots (10 μL) were treated with gel loading buffer (10 μL of 80 % formamide in TBE), heated at 95 oC
and resolved on denaturing PAGE. The gels were stained with Stains-All™ (Aldrich) to view the siRNA
decomposition patterns.

With metabolically stable constructs in hand, the RNAi activity of the CTP:siRNA
complexes was next evaluated in HepG2 hepatoblastoma cells (Figure 4.14). A CTP:siRNA
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complex (50:1 mole ratio, 20 µM) was prepared in binding buffer (50 mM Tris-HCl, pH 8.0, 100
mM NaCl, 5.0 mM EDTA) for transfection within the HepG2 cells. The transfected cells were
incubated (48 h, 37 oC, 5% CO2), lysed (RIPA lysis buffer, Invitrogen), and proteins were resolved
by SDS PAGE and transferred to a PVDF membrane for western blotting. Immunoblotting with
an anti-GRP78 primary antibody and a secondary antibody coupled to horseradish peroxidase
(HRP) detected the GRP78 expression levels. Analysis of the chemiluminescence produced by the
3,3’,5,5’-tetramethylbenzidine (TMB) substrate of HRP produced reduced GRP78 (~50%) at
quantities that were comparable to the benchmark Lipofectamine:siRNA transfections (Figure
4.14, A and B).17 When HepG2 cells were transfected with siRNA using lipofectamine as a
transfecting agent there was a 40-50% downregulation of GRP78 with 40-80 pmol siRNA
respectively,17 which is comparative with the results obtained with CTP:siRNA transfections of
HepG2 cells (Figure 4.14, A and B) This shows that the CTP provides a similar degree of
transfection thereby proving that these CTPs can be utilized as delivery vehicles for
marcomolecules into cells. Finally, a Trypan blue cell viability assay was used to track the number
of dead HepG2 cells (~15%) following GRP78 silencing (Figure 4.14, C), which validates the
RNAi activity for the CTP:siRNA constructs within HepG2 liver cancer cells.

Figure 4.14. RNAi activity of the CTP:siRNA complex in HepG2 cells. A) Western blot and B) data
analysis by autoradiography of GRP78 expression (n=1) following CTP:siRNA transfection (0, 40 and 80
pmol siRNA, 50:1 mole ratio CTP:siRNA, in Tris buffer pH 8). C) Cell viability data (0, 40 and 80 pmol
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siRNA, 50:1 mole ratio CTP:siRNA, 20 µM in 50 µL of OPTIMEM) determined by Trypan blue viability
assay (mean  S.E.M.; n=3, *P< 0.05). Data acquired in collaboration with Dr. Blake’s research group.

4.5 CONCLUSIONS
In this study, the biological activity of poly(arginine) derived Pep42 cancer-targeting
peptides, CTPs, has been evaluated. These peptides demonstrated the inherent ability to bind to
the GRP78 receptor, cell surface localized on HepG2 liver cancer cells. High affinity and selective
GRP78 binding was validated by flow cytometry and confocal microscopy underscoring their
potential utility as tumor-homing gene delivery agents. Towards this goal, CTPs were combined
with GRP78-silencing siRNAs to generate the putative CTP:siRNA complex. Characterization
studies of the CTP:siRNA complexes were performed by gel shift binding assays, which
ascertained the optimal CTP:siRNA stoichiometric ratios for complex formation. Additionally,
TEM, DLS and CD spectroscopy validated the sizes, shapes and higher-ordered nanostructures
formed between the CTP:siRNA. Thermal denaturation experiments were then performed to study
the changes in secondary structures of the CTPs and siRNAs during complex formation. A 10%
FBS in DMEM treatment was used to confirm their metabolic stability for cell-based assays. In
HepG2 hepatoblastoma cells, CTP-R9 demonstrated efficient siRNA transfection according to the
potent suppression of GRP78 expression (~50% at 40 pmol siRNA) and comparable cell deaths
(~15%) relative to the benchmark Lipofectamine:siRNA transfections that were previously
established.17 Thus, the CTPs developed in this study are not only applicable for efficient siRNA
transfections, but also formulate the basis of our cancer-targeting gene therapy approach.
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4.7 EXPERIMENTAL SECTION
4.7.1. FORMATION OF CTP:siRNA COMPLEXES
Poly(arginine)-Pep42 CTPs (Table 2.1, sequences 2.2-2.5) were added in increasing
concentrations (0.5-2.5 µmol) relative to the siRNA (0.5 μmol) in annealing buffer (50 mM TrisHCl, pH 8.0, 100 mM NaCl, 5.0 mM EDTA). The samples were incubated at 37 oC for 1 hour,
cooled to room temperature and incubated at 4 oC overnight.
4.7.2. POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) GEL SHIFT ASSAY OF
CTP:siRNA COMPLEXES
The CTP:siRNA samples were analyzed by adding stoichiometric ratios (13 µM, 1-50:1,
mol/mol) of CTP:siRNA in a 30% sucrose buffer (1X TAE, 10 µL). These complexes were then
analyzed by electrophoresis on a native 18% polyacrylamide gel (22.5 mL acrylamide and N,N’methylene bisacrylamide, 22.5 mL autoclaved water) in 10X TBE buffer, 22.5 mL (acrylamide
and N,N-methylene bisacrylamide) and 22.5 mL of autoclaved water (pH 8). The gel was run at
500 V for 2.5 hours, which was followed by detection with Stains-All™ for 2 hours in order to
visualize the CTP:siRNA bands.
4.7.3. STRUCTURAL AND THERMAL ANALYSIS OF CTP:siRNA COMPLEXES
The CTP-R9:siRNA complexes (1-50:1, 13 µM) were dissolved in phosphate buffer (140
mM KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4) and transferred to 1.0 mL silica quartz cuvette (1.0
cm path length) for CD spectroscopy on an Aviv 62A DS CD spectrophotometer (Lakefield, NJ).
The baselines for all the cuvettes in the presence of phosphate buffer were collected before each
sample scan was collected. Prior to sample analyses, the instrumental parameters relating to
bandwidth, time constant, scan rate and the number of scans were optimized. For sample
(CTP:siRNA) analyses, the bandwidth was optimized at 1 nm. The time constant or the scan rate
measures the time in which the CD data is averaged. The scan rate for the CD spectra collected in
this study was set at 0.5 min. The number of scans (N = 3) was performed on each sample to
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confirm reproducibility. The data was imported into Microsoft Excel and the CD spectra were
plotted in terms of molar ellipticity vs wavelength. The thermal stability of CTP-R9:siRNA (150:1, 13 µM) was determined using the same samples on a UV-Vis spectrophotometer at 260 nm
with increasing temperatures (5 - 95 °C).
4.7.4. DYNAMIC LIGHT SCATTERING (DLS)
DLS is a useful method for measuring the size of the peptide molecule. By shining the
monochromatic light of the laser on the samples in Brownian motion causes a Doppler Shift when
the light hits the moving particles changing the wavelength of the incoming light. By measuring
the diffusion coefficient the size distribution can be commuted as this change in wavelength is
related to the size of the particle.28 These DLS measurements were performed on a 90 plus particle
size analyzer (Brookhaven Instruments Corporation) employing a 90° scattering angle and a 35
mW incident laser (658 nm). Samples (13 µM) were diluted in a pH 7.0 buffer consisting of 140
mM KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4 and sonicated for 30 minutes before taking
measurements. The reported diameters are the average of 5 runs for each sample with the
corresponding standard deviations.
4.7.5. TRANSMISSION ELECTRON MICROSCOPY (TEM)
Transmission electron microscopy is a technique in which a beam of electrons is passed
through a thin specimen. Some of the electrons will interact with the specimen, however the
electrons that are transmitted through the specimen are magnified and focused on an image detector
that allows for an image of the specimen to be formed. This image provides the size of the particle
to be measured as well as the determination of aggregation which is very common with biological
molecules. The diluted samples from the DLS measurements were mixed in a 1:1 (v/v) ratio with
1% uranyl acetate in ethanol and sonicated for 10 minutes. An aliquot (5.0 µL) was transferred to
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a carbon film coated copper grid, 300 mesh (electron microscopy sciences, Hatfield, PA) and the
excess solution was removed immediately using an absorbent paper. The grids were dried
overnight and viewed under the transmission electron microscope (JEOL, model JEM-1200 EX).
Images were taken with a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc.)
using the software Maxim DL5 (Diffraction Limited, Ottawa, Canada).
4.7.6. HEPG2 CELL CULTURE
The human hepatoblastoma, HepG2 cells (American Type Culture Collection, Manhasset,
VA) were cultured in T25 cm2 and T75 cm2 flasks (Grenior Bio-one Cell star, FL) in Dulbecco’s
Modified Eagle Medium (DMEM) with GlutaMAX and heat-inactivated 10% Fetal Bovine Serum
(Gibco, CA), containing 1.0% penicillin/streptomycin (Gibco, CA), in an incubator set at 37 oC
with a humidified atmosphere of 5.0% CO2. Cells were routinely passaged at 75% confluence
using Dulbecco’s PBS (Gibco, CA) and 0.05% Trypsin-EDTA (1X), Phenol Red (Gibco, CA) and
then split into a 1:10 dish ratio. Cells used in the transfection experiments were cultured in 6 - 96well culture plates and allowed to recover for 24 hours before treatment.
4.7.7. FLOW CYTOMETRY
In flow cytometry, cells flow through a flow chamber rapidly one at a time, approximately
500 cells per second. A small laser beam of very bright light hits each cell and the fluorophore
present on the surface or within the cell absorbs the light of a particular wavelength and emits a
different wavelength of light that is detected as a specific color depending on the fluorophore.29 In
this manner cell population counts can be tracked by fluorescent signaling. HepG2 cell were plated
in DMEM at a concentration of 50,000 cells/mL in 12-well plates and incubated for 48 hours at
37°C. Cell monolayers were then washed with PBS (pH 7.4) and dissociated using cell dissociation
buffer (Life Technologies Corporation, Grand Island, NY). Cells were then labelled with either
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anti-GRP78 (N-20) mAb-AlexaFluor 488 (100 nM), or one of the following peptides (100 nM):
FITC-Pep42, FITC-Pep42-R3, FITC-Pep42-R6, FITC-Pep42-R9, FITC-Pep42-R12, or FITC-R9.
For the inhibition assays, cells were initially blocked with GRP78 N-20 blocking peptide (10
mg/mL), followed by incubation with either N20 mAb (100 nM) or with one of the FITC-Pep42
peptides. Expression of GRP78 on HepG2 cells and binding of the Pep42 peptides was assessed
by flow cytometry.
4.7.8. LASER SCANNING CONFOCAL MICROSCOPY
The application of laser scanning confocal microscopy allows for the identification of cells
and sub-microscopic components with a high degree of specificity through the use of multi-labeled
specimens.30 In this technique, a laser beam is focused through an aperture onto the surface of a
specimen. The beam of light is then scattered and recollected excluding the original excitation
wavelength which is used to form an image of the specimen.31
HepG2 cells were cultured at a cell density of 50,000 cells/mL in DMEM and plated on
sterile glass coverslips (22x22mm) in 6-well plates for 72 hours. After 72 hours, the media was
removed and replaced with fresh DMEM for 24 hours. Following incubation, the cells were
washed with PBS and fixed with a 2.0% paraformaldehyde solution in PBS for 7 minutes.
Coverslips were treated in the presence or absence of GRP78 N-20 blocking peptide (417 g/mL,
1:100 dilution in PBS) or in the presence of 1.0% BSA for 30 minutes at room temperature.
Following treatment, the coverslips were incubated with either anti-GRP78 (N-20) AlexaFluor 488
antibody (2.0 g/mL), FITC-Pep42, FITC-Pep42 R9, or FITC-R9 (1.0 g/mL, 1:1000 dilution in
PBS) and incubated for 2 hours at room temperature. Coverslips were washed with PBS,
counterstained with DAPI (0.5 µg/mL in PBS) for 3 minutes, washed a final time with PBS and
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viewed on a Confocal Laser Scanning Microscope with the 60X oil objective lens in combination
with the Olympusview software program.
4.7.9. CTP:siRNA TRANSFECTION IN HepG2 CELLS
HepG2 cells were transfected with the siRNAs, (40-80 pmol) and CTPs (4.0 nmol) in
binding buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5.0 mM EDTA). The HepG2 cell
monolayers were plated and incubated at 37 C with 5.0% CO2. After 24 h, the serum free basal
medium was removed and replaced with growth medium. Transfected cells were cultured (48 h)
and lysed (RIPA lysis buffer, Invitrogen) after transfection for analysis.
4.7.10. SDS-PAGE AND WESTERN BLOTTING
Cell lysates were resolved on NuPAGE 10% Bis-Tris gels and electroblotted onto
polyvinyldifluoride (PVDF) membranes. Membranes were treated for 90 min in a blocking buffer
containing 5% (w/v) of non-fat dehydrated milk to minimize non-specific binding. Total HepG2
cells’ GRP78 expression was immunodetected with a 1:200 dilution of anti-GRP78 N-20
antibodies. The membrane associated immunoreactivity was then detected using a 1:5000 dilution
of a horseradish peroxidase-conjugated anti-goat secondary antibody and detected using ECL Plus
chemiluminescence. The resulting autoradiograph was scanned, quantified with NIH ImageJ and
expressed as integrated pixel density.
4.7.11. CELL VIABILITY
Cell viability was determined in 24-well plates with HepG2 cells cultured in serum-free
basal medium for 24 h and then incubated in the presence or absence of varying concentrations of
CTP:siRNA (20 µM) for 48 h at 37 o C. The samples were removed with Enzyme Free Dissociation
Buffer for 3 minutes at 37 C. Samples were pelleted and re-suspended in Dulbucco’s PBS (1.0
mL) and Trypan blue 0.4% stain (100 µL) was added, a stain for only dead cells.17 Samples were
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quantified using a Countess automated cell counter. The resulting data was analyzed with
GraphPad Prism 4.0 and statistical significance was determined by ANOVA (p< 0.05).
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CHAPTER 5: CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE
5.1 CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS
THESIS
5.1.1 SYNTHESIS AND CHARACTERIZATION OF POLY(ARGININE) DERIVED
CANCER-TARGETING PEPTIDES
The rational design, solid phase synthesis and characterization of a small library (16) of
poly(arginine) cancer-targeting peptides has been realized in Chapter 2 of this thesis. These
peptides (Table 2.1) are based on the cyclic peptide Pep42 sequence, H2N-CTVALPGGYVRVCCONH2 known to selectively bind to cell surface GRP78 found on a number of different tumors
and not on normal cells. Arginine rich sequences have been shown to condense oligonucleotides
(eg. siRNA) and facilitate their cell translocation activity for applications in gene therapy. Towards
the development of a cancer-targeting gene therapy approach, a new series of Pep42-poly(L/Darginine) peptides with varying lengths of poly(L/D-arginine) sequences have been furnished in
this study. The synthesis strategy necessitated optimization of the conventional Fmoc-Solid Phase
Peptide Synthesis (Fmoc-SPPS) method. The use of a polar, highly swelling NovaPEG resin, based
on a polyethylene glycol matrix, was found to yield the best synthesis efficiencies for the nonpolar Pep42 and the amphipathic Pep42-poly(L/D-arginine) peptides. This is because the polar
NovaPEG resin reduces peptide aggregation and facilitates high yielding coupling reactions of
challenging Fmoc-amino acids, such as Fmoc-L/D-Arg(Pbf). Following Fmoc-SPPS, analysis and
purification by RP-LC/MS provided the desired peptides in good yield (10 - 46%) and purities
>95%. Confirmation of the identities of the peptide sequences was established by ESI-MS, which
indicated mass:ratios (m/z) that were consistent with the varying charged states of the
poly(arginine) sequences.
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With pure peptides in hand, their structural properties and thermal stabilities were next
assessed (Chapter 3). CD spectroscopy was used to determine peptide structures in various
solvents (water, phosphate buffer and 2,2,2-trifluoroethanol) followed by their thermal stabilities
in a physiologically relevant phosphate buffer. These experiments form the basis of our structureactivity relationship study, in an attempt to elucidate the influence of peptide structure on its
biological activity (Chapter 4). The peptides were found to exhibit folded structures in varying
solvents, readily transitioning between helical and turn conformations with little observation of
random coil or disordered structures at room temperature, 22 oC, (Figure 3.3-3.8). Interestingly,
the cyclic Pep42 sequence was found to display a helical-type structure in water and
trifluoroethanol, while in phosphate buffer, the peptide backbone torsion angles were found to
bend in a turn-type geometry. In comparison, the R9 sequence portrayed a distorted type turn
conformation in various solvent conditions. Meanwhile, the Pep42-poly(L/D-arginine) series
expectedly exhibited a combination of turn and helical geometries. The peptide folded structures
were also found to be generally resistant towards thermal denaturation at elevated temperatures
(45 – 85 °C). Turn-to-helix transitions were observed for the Pep42-poly(L/D-arginine) sequences
with increasing temperatures (25 – 85 °C) in water. It was rationalized that the disulfide bond
played a critical role in maintaining stable peptide folded structures, even at elevated temperatures
(45 – 85 °C). This hypothesis was confirmed by the reduction (DTT) of the Pep42 disulfide bond,
which revealed a helix-to-coil peptide transition at elevated temperatures (45 – 85 °C). With a
better understanding of peptide structure and bio-physical properties, peptide biology was next
examined towards the development of a targeted gene therapy approach in cancer cells (Chapter
4).
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5.1.2

BIOLOGICAL

ACTIVITY

OF

POLY(ARGININE)

DERIVED

CANCER-

TARGETING PEPTIDES IN HepG2 CANCER CELLS
In Chapter 4 of this thesis, the discovery of a new siRNA delivery vector for potential
applications in cancer-targeting gene therapy is described. In collaboration with the Blake and
Bitsaktsis research groups (Department of Biological Sciences, Seton Hall University) peptide
biology was realized. Initially, FACS analyses of FITC-labeled cancer-targeting peptides revealed
GRP78 binding on HepG2 liver cancer cells that mirrored the GRP78 binding affinity and
specificity of the FITC-labeled anti-GRP78 primary antibody. Thus, the poly-arginine derived
Pep42 sequences were found to behave as GRP78-targeting ligands on HepG2 liver cancer cells.
Moreover, the Pep42-poly(arginine) cancer-targeting peptides were not found to be toxic in HepG2
cells (<10% cell death) following a Trypan blue cell death staining assay. This result is important
for the safe administration of cancer-targeting peptides in cancer treatment regimens. This
revelation may be also applicable to other GRP78 overexpressing tumors, such as those belonging
but not limited to hepatocarcinoma, neuroblastoma, lymphoma and glioblastoma. Towards this
ultimate goal, the poly(arginine) derived cancer-targeting peptides were condensed with siRNA
targeting the GRP78 mRNA oncogene. PAGE, DLS, TEM, CD spectroscopy and thermal
denaturation experiments using UV-Vis spectroscopy demonstrated the formation of stable cancertargeting peptides:siRNA, CTP:siRNA, complexes. In HepG2 liver cancer cells, a representative
CTP:siRNA complex was transfected into the cells, cultured and assayed for GRP78 knockdown
and cell death activity. In this assay, GRP78 silencing (50-60%) and cell death (5-15%) were found
to be consistent with those observed from the benchmark Lipofectamine:siRNA transfections. This
result underscores the potential utility of the CTPs in the targeted delivery of siRNA in cancer cells
for potent and selective RNAi effects.
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Figure A1. RP-HPLC analysis of purified Pep42 (Table 2.1, sequence 2.1) using a linear gradient 2-82%
MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle size)
set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A2. ESI-LCMS analysis of purified Pep42 (Table 2.1, sequence 2.1) using a linear gradient 2-82%
MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle size)
set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A3. Representative RP-HPLC chromatograms of purified Pep42-R3 (Table 2.1, sequence 2.2)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A4. ESI-LCMS analysis of purified Pep42-R3 (Table 2.1, sequence 2.2) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A5. Representative RP-HPLC chromatograms of purified Pep42-R6 (Table 2.1, sequence 2.3)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.

114

Figure A6. ESI-LCMS analysis of purified Pep42-R6 (Table 2.1, sequence 2.3) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A7. ESI-LCMS analysis of purified Pep42-R9 (Table 2.1, sequence 2.4) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A8. Representative RP-HPLC chromatograms of purified Pep42-R12 (Table 2.1, sequence 2.5)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A9. ESI-LCMS analysis of purified Pep42-R12 (Table 2.1, sequence 2.5) using a linear gradient
2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A10. Representative RP-HPLC chromatograms of purified Pep42-r3 (Table 2.1, sequence 2.6)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A11. ESI-LCMS analysis of purified Pep42-r3 (Table 2.1, sequence 2.6) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.

120

Figure A12. Representative RP-HPLC chromatograms of purified Pep42-r6 (Table 2.1, sequence 2.7)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A13. ESI-LCMS analysis of purified Pep42-r6 (Table 2.1, sequence 2.7) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.

122

Figure A14. Representative RP-HPLC chromatograms of purified Pep42-r9 (Table 2.1, sequence 2.8)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A15. ESI-LCMS analysis of purified Pep42-r9 (Table 2.1, sequence 2.8) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A16. Representative RP-HPLC chromatograms of purified Pep42-r12 (Table 2.1, sequence 2.9)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A17. ESI-LCMS analysis of purified Pep42-r12 (Table 2.1, sequence 2.9) using a linear gradient
2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A18. Representative RP-HPLC chromatograms of purified FITC-Ahx-Pep42 (Table 2.1, sequence
2.10) using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column
(4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A19. ESI-LCMS analysis of purified FITC-Ahx-Pep42 (Table 2.1, sequence 2.10) using a linear
gradient 2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0
µm particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A20. Representative RP-HPLC chromatograms of purified FITC-Ahx-Pep42-R3 (Table 2.1,
sequence 2.11) using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RXC18 column (4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at
214 nm and B) linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column
(4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A21. ESI-LCMS analysis of purified FITC-Ahx-Pep42-R3 (Table 2.1, sequence 2.11) using a
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A22. Representative RP-HPLC chromatograms of purified FITC-Ahx-Pep42-R6 (Table 2.1,
sequence 2.12) using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RXC18 column (4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at
214 nm and B) linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column
(4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A23. ESI-LCMS analysis of purified FITC-Ahx-Pep42-R6 (Table 2.1, sequence 2.12) using a
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A24. Representative RP-HPLC chromatograms of purified FITC-Ahx-Pep42-R9 (Table 2.1,
sequence 2.13) using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RXC18 column (4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at
214 nm and B) linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column
(4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A25. ESI-LCMS analysis of purified FITC-Ahx-Pep42-R9 (Table 2.1, sequence 2.13) using a
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A26. Representative RP-HPLC chromatograms of purified FITC-Ahx-Pep42-R12 (Table 2.1,
sequence 2.14) using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RXC18 column (4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at
214 nm and B) linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column
(4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.

135

Figure A27. ESI-LCMS analysis of purified FITC-Ahx-Pep42-R12 (Table 2.1, sequence 2.14) using a
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A28. Representative RP-HPLC chromatograms of purified FITC-Ahx-R9 (Table 2.1, sequence
2.15) using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column
(4.6 x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A29. ESI-LCMS analysis of purified FITC-Ahx-R9 (Table 2.1 sequence 2.15) using a linear
gradient 2-82% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0
µm particle size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A30. Representative RP-HPLC chromatograms of purified Poly-R9 (Table 2.1, sequence 2.16)
using A) linear gradient 2-82% MeCN/H2O (0.1% TFA) over 18 min with a Zorbax RX-C18 column (4.6
x 250 mm, 5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm and B)
linear gradient 2-82% MeOH/H2O (0.1% FA) over 18 min with a Zorbax RX-C18 column (4.6 x 250 mm,
5.0 µm particle size) at 25 °C and flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A31. ESI-LCMS analysis of purified Poly-R9 (Table 2.1, sequence 2.16) using a linear gradient 282% MeOH/H2O (0.1% FA) over 18 min using a Zorbax RX-C18 column (4.6 x 250 mm, 5.0 µm particle
size) set at a temperature of 25 °C at a flow rate of 1.0 mL/min with detection at 214 nm.
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Figure A32. CD spectra for Pep42-r3 (Table 2.1, sequence 2.6, 50 µM) in water, TFE and PBS at 25 °C.
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Figure A33. Temperature dependent (25 – 85 oC) CD spectra for Pep42-r3 (Table 2.1, sequence
2.6, 50 µM).
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Figure A34. CD spectra for Pep42-r6 (Table 2.1, sequence 2.7, 50 µM) in water, TFE and PBS at 25 °C.
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Figure A35. Temperature dependent (25 – 85 oC) CD spectra for Pep42-r6 (Table 2.1, sequence 2.7, 50
µM).
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Figure A36. CD spectra for Pep42-r9 (Table 2.1, sequence 2.8, 50 µM) in water, TFE and PBS at 25 °C.
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Figure A37. Temperature dependent (25 – 85 oC) CD spectra for Pep42-r9 (Table 2.1, sequence 2.8, 50
µM).
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Figure A38. CD spectra for Pep42-r12 (Table 2.1, sequence 2.9, 50 µM) in water, TFE and PBS at 25
°C.
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Figure A39. Temperature dependent (25 – 85 oC) CD spectra for Pep42-r12 (Table 2.1, sequence 2.9, 50
µM).
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Figure A40. Flow cytometry data on HepG2 cells. FITC signaling collected at 521 nm HepG2 cells (50,
000 cells/mL) in the presence of Alexa Fluor 488-labeled N20-anti-GRP78 primary antibody (100 nM) and
FITC-labeled poly(arginine) peptides (100 nM) without (a, c, e, g) and with (b, d, f, h) peptide blocker (10
mg/mL). Data acquired in collaboration with Drs. Blake and Bitsaktsis research groups.
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Figure A41. Laser scanning confocal microscopy of HepG2 cells. (a) FITC-Pep42 (b) FITC-Pep42 with
N-20 GRP78 blocking peptide (2.0 µg/mL) (c) FITC-Poly-R9 and (d) FITC-Poly-R9 with N-20 GRP78
blocking peptide (2.0 µg/mL). HepG2 cells (50, 000 cells/mL) were incubated with FITC-Pep42 and FITCPoly-R9 (2.0 µg/mL) and counterstained with DAPI (0.5 µg/mL in PBS). The FITC signal from the peptides
is visualized as green whereas DAPI stains the cells’ nuclei blue. Data acquired in collaboration with Drs.
Blake and Bitsaktsis research groups.
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Figure A42. Native PAGE gel shift assay of siRNA:CTP (1:1-50 mol:mol, 1 µmol). siRNA with Dye (Lane
A); siRNA:Pep42-R9 Lane B, 1:1; Lane C, 1:25; Lane D, 1:50; siRNA:Pep42-R12 Lane E, 1:1; Lane F,
1:25; Lane G, 1:50; branch siRNA (Lane H); branch siRNA:Pep42-R12 Lane I, 1:1; Lane J, 1:25; Lane
K,1:50; hyperbranch siRNA (Lane L); hyperbranch siRNA:Pep42-R12 Lane M, 1:1; Lane N, 1:25, Lane
O, 1:50.
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Figure A43. CD spectra of siRNA:Pep42 complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A44. CD spectra of siRNA:Pep42-R3 complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A45. CD spectra of siRNA:Pep42-R12 complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A46. CD spectra of siRNA:R9 complexes (13 μM, 1-50:1 mol/mol) in PBS (137 mM NaCl, 2.7
mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A47. CD spectra of branch siRNA(Y):Pep42-R3 complexes (13 μM, 1-50:1 mol/mol) in PBS (137
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A48. CD spectra of branch siRNA(Y):Pep42-R9 complexes (13 μM, 1-50:1 mol/mol) in PBS (137
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A49. CD spectra of branch siRNA (Y):Pep42-R12 complexes (13 μM, 1-50:1 mol/mol) in PBS
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A50. CD spectra of hyperbranch siRNA (1-2):Pep42-R3 complexes (13 μM, 1-50:1 mol/mol) in
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A51. CD spectra of hyperbranch siRNA (1-2):Pep42-R9 complexes (13 μM, 1-50:1 mol/mol) in
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A52. CD spectra of hyperbranch siRNA (1-2):Pep42-R12 complexes (13 μM, 1-50:1 mol/mol) in
PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4 adjusted to pH 7.4) at 25 oC.
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Figure A53. TEM image of Pep42-R9 (Table 2.1, sequence 2.4) showing different populations. Mostly
prevalent are populations ranging from 30 -100 nm which are probably the monomeric forms of the peptide.
There are some larger sizes present (approx. 200nm) which look like aggregates of the smaller ones. Data
acquired in collaboration with Dr. Samuni (Queen’s College CUNY).
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Figure A54. TEM images of branch siRNA generating well distributed uniform particles, average size 2025 nm. Sample (0.13 μM) were mixed with 1.0% uranyl acetate in ethanol (1:1 v/v), sonicated for 10
minutes, and added to a carbon film coated copper grid, 300 mesh (electron microscopy sciences, Hatfield,
PA) and dried overnight prior to viewing under the transmission electron microscope (JEOL, model JEM1200 EX). Images were taken with a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc.)
using the software Maxim DL5 (Diffraction Limited, Ottawa, Canada). Data acquired in collaboration with
Dr. Samuni (Queen’s College CUNY).
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Figure A55. TEM images of branch siRNA:CTP-R9 complex. The TEM image of complex branch
siRNA:CTP-R9 shows a population with a size range of 50 – 100 nm (circular shaped complexes). A
population of smaller particles of about 10 nm is also seen which is likely to be the control siRNA. The
complex (0.13 μM) was mixed with 1.0% uranyl acetate in ethanol (1:1 v/v), sonicated for 10 minutes, and
added to a carbon film coated copper grid, 300 mesh (electron microscopy sciences, Hatfield, PA) and dried
overnight prior to viewing under the transmission electron microscope (JEOL, model JEM-1200 EX).
Images were taken with a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc.) using the
software Maxim DL5 (Diffraction Limited, Ottawa, Canada). Data acquired in collaboration with Dr.
Samuni (Queen’s College CUNY).
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Figure A56. TEM image of hyperbranch siRNA. There is a range of sizes of the hyperbranch siRNA. The
prevalent population is the spherical monomer particles with an approximate size of 25 nm. There is a minor
fraction of medium size particles in the range of 100 nm (not seen in this picture) and a few large aggregates
(700-2000 nm). Sample (0.13 μM) was mixed with 1.0% uranyl acetate in ethanol (1:1 v/v), sonicated for
10 minutes, and added to a carbon film coated copper grid, 300 mesh (electron microscopy sciences,
Hatfield, PA) and dried overnight prior to viewing under the transmission electron microscope (JEOL,
model JEM-1200 EX). Images were taken with a SIA–L3C CCD camera (Scientific Instruments and
Applications, Inc.) using the software Maxim DL5 (Diffraction Limited, Ottawa, Canada). Data acquired
in collaboration with Dr. Samuni (Queen’s College CUNY).
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Figure A57. TEM image of hyperbranch siRNA:Pep42-R9. Uniformly distributed circular shaped
complexes sizes 300-500 nm. This population correlates with the one seen in DLS (340 nm). Also seen are
smaller sized particles (approx. 100-300 nm). These may be smaller complexes. Complex (0.13 μM) was
mixed with 1.0% uranyl acetate in ethanol (1:1 v/v), sonicated for 10 minutes, and added to a carbon film
coated copper grid, 300 mesh (electron microscopy sciences, Hatfield, PA) and dried overnight prior to
viewing under the transmission electron microscope (JEOL, model JEM-1200 EX). Images were taken with
a SIA–L3C CCD camera (Scientific Instruments and Applications, Inc.) using the software Maxim DL5
(Diffraction Limited, Ottawa, Canada). Data acquired in collaboration with Dr. Samuni (Queen’s College
CUNY).
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Figure A58. Thermal denaturation studies of the siRNA (duplex):Pep42 complex. Samples were prepared
by mixing siRNA:Pep42 (15 μM, 1-50:1 mol/mol) in phosphate buffer (140 mM KCl, 1.0 mM MgCl2, 5.0
mM NaHPO4) and placing on a heat block incubator set at 37 oC for 1 hour. Samples were cooled to room
temperature and placed in the fridge overnight prior to thermal denaturation studies. Samples were then
placed in a temperature regulated (5 oC) cell holder and heated (5 – 95 oC) for sample absorption
measurements at 260 nm.
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Figure A59. Thermal denaturation studies of the branch siRNA(Y):Pep42-R3 complex. Samples were
prepared by mixing branch siRNA(Y):Pep42-R3 (15 μM, 1-50:1 mol/mol) in phosphate buffer (140 mM
KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4) and placing on a heat block incubator set at 37 oC for 1 hour.
Samples were cooled to room temperature and placed in the fridge overnight prior to thermal denaturation
studies. Samples were then placed in a temperature regulated (5 oC) cell holder and heated (5 – 95 oC) for
sample absorption measurements at 260 nm.
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Figure A60. Thermal denaturation studies of the siRNA (duplex):Pep42-R3 complex. Samples were
prepared by mixing siRNA (duplex):Pep42-R3 (15 μM, 1-50:1 mol/mol) in phosphate buffer (140 mM
KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4) and placing on a heat block incubator set at 37 oC for 1 hour.
Samples were cooled to room temperature and placed in the fridge overnight prior to thermal denaturation
studies. Samples were then placed in a temperature regulated (5 oC) cell holder and heated (5 – 95 oC) for
sample absorption measurements at 260 nm.
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Figure A61. Thermal denaturation studies of the hyperbranch siRNA (1-2):Pep42-R3 complex. Samples
were prepared by mixing hyperbranch siRNA (1-2):Pep42-R3 (15 μM, 1-50:1 mol/mol) in phosphate buffer
(140 mM KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4) and placing on a heat block incubator set at 37 oC for 1
hour. Samples were cooled to room temperature and placed in the fridge overnight prior to thermal
denaturation studies. Samples were then placed in a temperature regulated (5 oC) cell holder and heated (5
– 95 oC) for sample absorption measurements at 260 nm.
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Sample

Effective Diameter from DLS (nm)

Pep42-R9

40 ± 4

Branch (Y) siRNA

170 ± 9

Pep42-R9: branch siRNA (Y)

900 ± 50
170 ± 9

Hyperbranch (1-2) siRNA

20-2000

Pep42R9:hyperbranch
siRNA (1-2)

340 ± 2

Table A62. Samples (0.05-0.15 μM) were prepared in pre-filtered (0.2 μm filter) pH 7.0 phosphate buffer
(140 mM KCl, 1.0 mM MgCl2, 5.0 mM NaHPO4) and sonicated for 30 minutes before taking
measurements. The reported diameter is the average of 5 runs for each sample reported with the standard
deviations about the mean. Data acquired in collaboration with Dr. Samuni (Queen’s College CUNY).
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